Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 2457. Отображено 100.
05-01-2012 дата публикации

Organic semiconductor material and organic thin-film transistor

Номер: US20120001162A1
Принадлежит: Kyushu Institute of Technology NUC

An organic thin-film transistor comprising a gate electrode, a gate insulator layer, an organic semiconductor layer, a source electrode and a drain electrode wherein the organic semiconductor layer consists of the organic semiconductor material having the structure represented by the general formula (1) shown below, and the organic semiconductor layer has crystallinity: wherein L represents a bivalent linker group having the structure consisting of one group or any combination of two or more groups selected from unsubstituted or fluorinated benzene residue, unsubstituted or fluorinated thiophene residue, unsubstituted or fluorinated thienothophene residue; R 1 represents carbonyl group, cyano group or C 1 -C 6 fluorinated alkyl group; R 2 represents halogen atom, cyano group, carbonyl group or acetyl group.

Подробнее
05-01-2012 дата публикации

Chemically stable ingredients as lemon odorant

Номер: US20120003170A1
Автор: Peter Fankhauser
Принадлежит: FIRMENICH SA

The present invention discloses certain nitrile compounds that are chemically stable and are useful as a lemon odorant or to impart a lemon odor to various consumer articles. The invention also relates to the compositions and articles that contain such compounds as well to the use of the compounds in a method of imparting a lemon odor to the compositions and articles.

Подробнее
26-01-2012 дата публикации

Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex

Номер: US20120022116A1
Принадлежит: Corning Inc

Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III):

Подробнее
04-04-2013 дата публикации

SWITCH ELEMENT COMPRISING A LIQUID-CRYSTALLINE MEDIUM

Номер: US20130083284A1
Автор: Junge Michael

The present invention relates to a switch element, which is thermo-responsive and which switches between a less transmissive state for radiant energy and a more transmissive state for radiant energy, and which comprises a liquid-crystalline medium. The invention furthermore relates to the use of the switch element for the regulation of radiant energy flow between interior spaces and the environment and for the regulation of the temperature of interior spaces. The invention furthermore relates to a liquid-crystalline medium, characterised in that it comprises 5-60% of a compound of the formula (I), in particular for use in the switch elements according to the invention. 8. Switch element according to claim 1 , characterised in that X is on each occurrence claim 1 , identically or differently claim 1 , selected from F and Cl.9. Switch element according to claim 1 , characterised in that the total concentration of the compounds of the formula (I) is between 5 and 60%.10. Switch element according to claim 2 , characterised in that the total concentration of the compounds of the formulas (I) and (II) is between 40 and 100%.11. Switch element according to claim 1 , characterized in that no electrical wiring claim 1 , circuitry and/or switching network is present.13. Use of a liquid-crystalline medium according to in a thermoresponsive optical switch element.14. Composite system comprising a liquid-crystalline medium according to and a polymer claim 12 , preferably a microporous polymer.15. A method for the regulation of the flow of radiant energy between an interior space and the environment claim 1 , which comprises regulating the flow with a switch element according to . The present invention relates to a switch element, which is thermo-responsive and which switches between a less transmissive state for radiant energy and a more transmissive state for radiant energy, and which comprises a liquid-crystalline medium. The invention furthermore relates to the use of the ...

Подробнее
11-04-2013 дата публикации

PYRETHRINOID-TYPE ESTERS AS PESTICIDES

Номер: US20130090381A1
Автор: Matsuo Noritada
Принадлежит: Sumitomo Chemical Company, Limited

An ester compound represented by formula (1): wherein Rrepresents Rrepresents 2-propenyl or 2-propynyl; Rrepresents hydrogen or methyl, Rrepresents hydrogen or C1-C4 alkyl, and Rrepresents hydrogen or C1-C4 alkyl; has an excellent pest control effect and is therefore useful as an active ingredient of a pest control agent. 2. The ester compound according to claim 1 , wherein a relative configuration of the substituent at the 1-position of the cyclopropane ring and the substituent at the 3-position of the cyclopropane ring is a trans configuration in formula (1).3. The ester compound according to claim 1 , wherein an absolute configuration of the 1-position of the cyclopropane ring is an R configuration in formula (1).4. The ester compound according to claim 1 , wherein an absolute configuration of the 1-position of the cyclopropane ring is an R configuration claim 1 , and a relative configuration of the substituent at the 1-position of the cyclopropane ring and the substituent at the 3-position of the cyclopropane ring is a trans configuration in formula (1).5. The ester compound according to claim 1 , wherein a relative configuration of the substituent of the 1′-position existing on the substituent at the 3-position of the cyclopropane ring is Z-configuration in formula (1).6. The ester compound according to claim 1 , wherein an absolute configuration of the 1-position of the cyclopropane ring is an R configuration and a relative configuration of the substituent of the 1′-position existing on the substituent at the 3-position of the cyclopropane ring is Z-configuration in formula (1).7. The ester compound according to claim 1 , wherein an absolute configuration of the 1-position of the cyclopropane ring is an R configuration claim 1 , a relative configuration of the substituent at the 1-position of the cyclopropane ring and the substituent at the 3-position of the cyclopropane ring is a trans configuration claim 1 , and a relative configuration of the substituent of ...

Подробнее
05-09-2013 дата публикации

Novel Intermediate for Preparing Tapentadol or Analogues Thereof

Номер: US20130231478A1
Принадлежит:

The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production. 2. The compound according to claim 1 , wherein Ris selected from Cl claim 1 , methyl claim 1 , OH claim 1 , NHor methoxy.3. The compound according to claim 1 , characterized in that Y is selected from OR claim 1 , wherein Ris selected from methyl claim 1 , ethyl claim 1 , n-propyl or isopropyl.4. The compound according to claim 1 , characterized in that Y is selected from NRR claim 1 , wherein R claim 1 , Rand N form substituted or unsubstituted saturated nitrogen-containing heteorcyclyl containing oxygen or not jointly.5. The compound according to claim 4 , wherein R claim 4 , Rand N form tetrahydropyrrole ring claim 4 , piperidine ring claim 4 , 4-methylpiperidine ring claim 4 , morpholine ring claim 4 , methylpiperazine ring or 4-hydroxypiperidine jointly.6. The compound according to claim 1 , selected from the following compounds:valeryl 2-methyl-3-(3-methoxyphenyl)chloride;methyl 2-methyl-3-(3-methoxyphenyl)sulfovalerate;methyl 2-methyl-3-(3-hydroxyphenyl) ulfovalerate;2-methyl-3-(3-hydroxyphenyl)sulfovaleramide;N,N-dimethyl-2-methyl-3-(3-methoxyphenyl)sulfovaleramide;N,N-dimethyl-2-methyl-3-(3-hydroxyphenyl)sulfovaleramide;N,N-diethyl-2-methyl-3-(3-methoxyphenyl)valeramide;3-(3-methoxyphenyl)-2-methyl-1-(piperidin-1-yl)pentan-1-one;3-(3-methoxyphenyl)-2-methyl-1-(4-methylpiperidin-1-yl)pentan-1-one;3-(3-methoxyphenyl)-2-methyl-1-(morpholin-1-yl)pentan- ...

Подробнее
27-03-2014 дата публикации

Functionalized Resins Obtained Via Olefin Metathesis

Номер: US20140088277A1
Принадлежит:

This invention relates to a reaction product obtained by contacting a polymer comprising units derived from dicyclopentadiene with a vinyl terminated macromonomer, a vinyl monomer or a vinylene monomer, in the presence of a metathesis catalyst, where the vinyl monomer or vinylene monomer is represented by the formula: 2. The composition of claim 1 , wherein Rand Rare hydrogen atoms.4. The tackifier of claim 3 , wherein the metathesis catalyst is a ruthenium catalyst.5. The tackifier of claim 3 , wherein the metathesis catalyst comprises 1 claim 3 ,3-bis(2 claim 3 ,4 claim 3 ,6-trimethylphenyl)-4 claim 3 ,5-dihydroimidazol-2-ylidene[2-(i-propoxy)-5-(N claim 3 ,N-dimethylaminosulfonyl)phenyl]methyleneruthenium(II)dichloride claim 3 , tricyclohexylphosphine[1 claim 3 ,3-bis(2 claim 3 ,4 claim 3 ,6-trimethylphenyl)imidazol-2-ylidene][3-phenyl-1H-inden-1-ylidene]ruthenium(II)dichloride claim 3 , tricyclohexylphosphine[3-phenyl-1H-inden-1-ylidene][1 claim 3 ,3-bis(2 claim 3 ,4 claim 3 ,6-trimethylphenyl)-4 claim 3 ,5-dihydro-imidazol-2-ylidene]ruthenium(II) dichloride claim 3 , tricyclohexylphosphine[1 claim 3 ,3-bis(2 claim 3 ,4 claim 3 ,6-trimethylphenyl)-4 claim 3 ,5-dihydroimidazol-2-ylidene][(phenylthio)methylene]ruthenium(II)dichloride claim 3 , bis(tricyclohexylphosphine)-3-phenyl-1H-inden-1-ylideneruthenium(II)dichloride claim 3 , 1 claim 3 ,3-Bis(2 claim 3 ,4 claim 3 ,6-trimethylphenyl)-4 claim 3 ,5-dihydroimidazol-2-ylidene[2-(i-propoxy)-5-(N claim 3 ,N-dimethylaminosulfonyl)phenyl]methyleneruthenium(II)dichloride claim 3 , [1 claim 3 ,3-bis(2 claim 3 ,4 claim 3 ,6-trimethylphenyl)-2-imidazolidinylidene]-[2-[[(4-methylphenyl)imino]methyl]-4-nitrophenolyl]-[3-phenyl-1H-inden-1-ylidene]ruthenium(II) chloride claim 3 , 1 claim 3 ,3-Bis(2 claim 3 ,4 claim 3 ,6-trimethylphenyl)-4 claim 3 ,5-dihydroimidazol-2-ylidene[2-(i-propoxy)-5-(N claim 3 ,N-dimethylaminosulfonyl)phenyl]methyleneruthenium(II)dichloride claim 3 , Tricyclohexylphosphine[3-phenyl-1H-inden-1-ylidene ...

Подробнее
02-01-2020 дата публикации

METHODS AND COMPOSITIONS FOR TERPENOID TRICYCLOALKANE SYNTHESIS

Номер: US20200002272A1
Принадлежит:

In one aspect, the disclosure relates to methods for preparation of intermediates useful for the preparation of terpenoid cores. In a further aspect, the disclosed methods pertain to the preparation of compounds comprising a terpenoid core or scaffold, such as 6/7/5 tricycloalkanes. The disclosed methods utilize abundant starting materials and simple reaction sequences that can be used to tunably and scalably assemble common terpenoid cores. In various aspects, the present disclosure pertains to compounds prepared using the disclosed methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. 120-. (canceled)22. The method of claim 21 , wherein the metal hydride is LiH claim 21 , NaH claim 21 , or KH.23. The method of claim 21 , wherein E is —CN or —(C═O)OCH.24. The method of claim 21 , wherein E is —CN.25. The method of claim 21 , wherein each of R claim 21 , R claim 21 , R claim 21 , and Ris independently hydrogen claim 21 , methyl claim 21 , phenyl claim 21 , or —CH(C═O)OCH.26. The method of claim 21 , wherein each of Rand Rare hydrogen; and wherein Rand Rare covalently bonded and claim 21 , together with more intermediate carbons claim 21 , comprise —CHCH— or —CH═CH—.27. The method of claim 21 , wherein Ris hydrogen claim 21 , methyl claim 21 , phenyl claim 21 , or —CH(C═O)OCH.28. The method of claim 21 , wherein Ais —CH— claim 21 , —CHCH claim 21 , —CH(C═O)OCHCH claim 21 , or —N(C═O)OC(CH).29. The method of claim 21 , wherein Ris hydrogen claim 21 , methyl claim 21 , phenyl claim 21 , trimethylsilyl claim 21 , or —CH(C═O)OCH.341. The method of claim claim 21 , wherein E is —CN or —(C═O)OCH.351. The method of claim claim 21 , wherein E is —CN.361. The method of claim claim 21 , wherein each of R claim 21 , R claim 21 , R claim 21 , and Ris independently hydrogen claim 21 , methyl claim 21 , phenyl claim 21 , or —CH(C═O)OCH.371. The method of claim claim 21 , ...

Подробнее
14-01-2016 дата публикации

3'-substituted-abscisic acid derivatives

Номер: US20160007598A1
Принадлежит: Valent BioSciences LLC

The invention relates to a novel class of (S)-3′-substituted-abscisic acid derivatives and (±)-3′-substituted-abscisic acid derivatives, and methods of synthesizing the derivatives.

Подробнее
09-01-2020 дата публикации

SUBSTRATE TREATMENT METHOD, SUBSTRATE TREATMENT SYSTEM AND DIRECTED SELF-ASSEMBLING MATERIAL

Номер: US20200013617A1
Принадлежит: JSR Corporation

A substrate treatment method includes: overlaying a film on a surface of a substrate which includes a first region including a metal atom in a surface layer thereof, using a directed self-assembling material which contains a compound having no less than 6 carbon atoms and including at least one cyano group. After the overlaying, the film on a region other than the first region is removed. After the removing, a pattern principally containing a metal oxide is formed by an Atomic Layer Deposition process or a Chemical Vapor Deposition process on the region other than the first region, of the surface of the substrate. 1. A substrate treatment method comprising:overlaying a film on a surface of a substrate which comprises a first region comprising a metal atom in a surface layer thereof, using a directed self-assembling material which comprises a compound having no less than 6 carbon atoms and comprising at least one cyano group;after the overlaying, removing the film on a region other than the first region; andafter the removing, forming a pattern principally comprising a metal oxide by an Atomic Layer Deposition process or a Chemical Vapor Deposition process on the region other than the first region, of the surface of the substrate.3. The substrate treatment method according to claim 1 , further comprising after the forming of the pattern claim 1 , removing the compound that remains in the first region.4. The substrate treatment method according to claim 1 , wherein the overlaying comprises applying the directed self-assembling material on the surface of the substrate.5. A substrate treatment system comprising:a mechanism for overlaying a film on a surface of a substrate which comprises a first region comprising a metal atom in a surface layer thereof, using a directed self-assembling material which comprises a compound having no less than 6 carbon atoms and comprising at least one cyano group;a mechanism for removing the film on a region other than the first region, ...

Подробнее
24-01-2019 дата публикации

ANTICONVULSANT COMPOUNDS

Номер: US20190023651A1
Принадлежит:

The present application relates to compounds and methods for reducing the severity of convulsant activity, or epileptic seizures. 2. The compound of claim 1 , wherein R═CH claim 1 , linear or branched Cto C claim 1 , cCH claim 1 , cCH claim 1 , or cCC.3. The compound of claim 2 , wherein R═H or CH.4. The compound of claim 3 , wherein R═CH claim 3 , or linear or branched Cto C.5. The compound of claim 4 , wherein R═CH.6. The compound of claim 1 , wherein the compound represented by the formula (I) is 2-(3 claim 1 ,5 claim 1 ,5-trimethylcyclohex-2-en-1-ylidene)pentanenitrile.7. The compound of claim 1 , wherein the compound represented by the formula (I) is 3-methyl-2-(3 claim 1 ,5 claim 1 ,5-trimethylcyclohex-2-en-1-ylidene)butanenitrile.12. The pharmaceutical composition of claim 11 , wherein R═CH claim 11 , linear or branched Cto C claim 11 , cCH claim 11 , cCH claim 11 , or cCC.13. The pharmaceutical composition of claim 12 , wherein R═H or CH.14. The pharmaceutical composition of claim 13 , wherein R═CH claim 13 , or linear or branched Cto C.15. The pharmaceutical composition of claim 14 , wherein R═CH.16. The pharmaceutical composition of claim 11 , wherein the compound represented by the formula (I) is 2-(3 claim 11 ,5 claim 11 ,5-trimethylcyclohex-2-en-1-ylidene)pentanenitrile.17. The pharmaceutical composition of claim 11 , wherein the compound represented by the formula (I) is 3-methyl-2-(3 claim 11 ,5 claim 11 ,5-trimethylcyclohex-2-en-1-ylidene)butanenitrile. The present invention relates to compounds with anti-convulsant and pain activity. These compounds are useful in modulating voltage-gated sodium channel activity and are thus useful in the treatment of epilepsy and chronic or acute pain.Anti-convulsant compounds are presently in wide use in the treatment of a variety of conditions and diseases, including epilepsy. Epilepsy is a neurological condition which affects the nervous system and causes individuals with epilepsy to suffer from seizures. These ...

Подробнее
24-01-2019 дата публикации

SHIP1 MODULATORS AND METHODS RELATED THERETO

Номер: US20190023709A1
Принадлежит:

Compounds of formula (I): 2. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is substituted with one hydrogen;C14 is substituted with one hydrogen;C15 is substituted with two hydrogens;{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 4a', '4b', '7', '3, 'sub': 2', '2', '2', '2', '3', '3, 'Ris hydrogen or alkyl, Ris a direct bond to the carbon to which Ris attached, and Ris —CHNHor —CHN(H)C(O)(CH)CH;'}{'sup': '5', 'Ris alkyl;'}{'sup': '6', 'Ris hydrogen;'}{'sup': '7', 'Ris hydrogen;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain; and'}{'sup': '9', 'each Ris independently hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl.'}3. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is substituted with one hydrogen;C14 is substituted with one hydrogen;C15 is substituted with two hydrogens;{'sup': '1', 'Ris —OH;'}{'sup': '2', 'sub': '2', 'Ris —CH—OH;'}{'sup': 4a', '4b', '7', '3, 'sub': 2', '2', '2', '2', '3', '3, 'Ris hydrogen or methyl, Ris a direct bond to the carbon to which Ris attached, and Ris —CHNHor —CHN(H)C(O)(CH)CH;'}{'sup': '5', 'Ris methyl;'}{'sup': '6', 'Ris hydrogen; and'}{'sup': '7', 'Ris hydrogen.'}4. The compound of selected from:(1S,3S,4R)-4-((3aS,6S,7R,7aS)-7-(aminomethyl)-3,3a-dimethyl-3a,4,5,6,7,7a-hexahydro-1H-inden-6-yl)-3-(hydroxymethyl)-4-methylcyclohexanol; andN-(((3aR,6S,7R,7aS)-6-((1R,2S,4S)-4-hydroxy-2-(hydroxymethyl)-1-methylcyclohexyl)-3a-methyl-3a,4,5,6,7,7a-hexahydro-1H-inden-7-yl)methyl)pentanamide.6. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is ...

Подробнее
04-02-2016 дата публикации

SHIP1 MODULATORS AND METHODS RELATED THERETO

Номер: US20160031899A1
Принадлежит:

Compounds of formula (II): wherein A, R, R, Rand Rare described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. 3. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each independently hydrogen, alkyl, alkenyl or alkynyl;'}{'sup': 4a', '4b', '7, 'or Ris hydrogen, alkyl, alkenyl or alkynyl and Ris a direct bond to the carbon to which Ris attached;'}{'sup': 4a', '4b, 'or Rand Rtogether form alkylidene or haloalkylidene;'}{'sup': 5', '5, 'Ris alkyl or Ris a direct bond to the carbon at C14;'}{'sup': 6', '8', '9', '8', '9, 'sub': '2', 'Ris hydrogen, —R—ORor —R—N(R);'}{'sup': 7', '8', '9', '8', '9', '7', '4b', '7, 'sub': '2', 'Ris hydrogen, —R—OR, —R—N(R), or a direct bond to C15, provided that when Ris a direct bond to C15, Ris not a direct bond to the carbon to which Ris attached;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain;'}{'sup': '9', 'each Ris hydrogen, alkyl, optionally substituted aryl and optionally substituted aralkyl;'}{'sup': '9a', 'each Ris hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl;'}optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, ...

Подробнее
09-02-2017 дата публикации

SMALL MOLECULE ANALOGS OF E4orf1

Номер: US20170037064A1
Принадлежит:

The invention relates to amino nitrile compounds. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis. 5. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable vehicle.6. A method of treating a disease comprising administering to a subject a therapeutically effective amount of a compound of .7. The method of claim 6 , wherein the disease is selected from the group consisting of hyperglycemia claim 6 , insulin resistance claim 6 , metabolic syndrome claim 6 , polycystic ovary syndrome (PCOS) claim 6 , prediabetes claim 6 , diabetes type 1 claim 6 , diabetes type 2 claim 6 , hepatic steatosis claim 6 , NAFLD claim 6 , non-alcoholic steato-hepatitis (NASH) claim 6 , and liver dysfunction (e.g. claim 6 , liver dysfunction characterized by fatty liver and/or insulin resistance) claim 6 , and combinations thereof.8. A method of treating a disease comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition of .9. The method of claim 8 , wherein the disease is selected from the group consisting of hyperglycemia claim 8 , insulin resistance claim 8 , metabolic syndrome claim 8 , polycystic ovary syndrome (PCOS) claim 8 , prediabetes claim 8 , diabetes type 1 claim 8 , diabetes type 2 claim 8 , hepatic steatosis claim 8 , NAFLD claim 8 , non-alcoholic steato-hepatitis (NASH) claim 8 , and liver dysfunction (e.g. claim 8 , liver dysfunction characterized by fatty liver and/or insulin resistance) claim 8 , and combinations thereof. This application claims the benefit of U.S. Provisional Application No. 61/983,142, filed Apr. 23, 2014 the entire disclosure of which is hereby incorporated by reference herein.The world is in the middle of an obesity epidemic, which appears to be followed by an epidemic of type 2 diabetes. Although lifestyle modification to induce weight loss is a cornerstone of preventing and treating diabetes, inducing a ...

Подробнее
08-02-2018 дата публикации

PERFUME SYSTEMS

Номер: US20180037843A1
Принадлежит:

The present application relates to perfume raw materials, perfume delivery systems and consumer products comprising such perfume raw materials and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials and compositions, including the delivery systems, disclosed herein expand the perfume communities' options as such perfume raw materials can provide variations on character and such compositions can provide desired odor profiles. 1. A perfume raw material selected from Table 1 Nos. (S)-2 ,2-dimethyl-3-(4-(prop-1-en-2-yl)cyclohex-1-enyl)propanenitrile; 3-cyclopropyl-2-(cyclopropylmethyl)-2-methylpropanenitrile; 1-(cyclopropylmethyl)cyclo-propanecarbonitrile; (S)-3 ,3-dimethyl-4-(4-(prop-1-en-2-yl)cyclohex-1-enyl)butan-2-one; 3 ,3-dimethyl-4-((S)-4-(prop-1-en-2-yl)cyclohex-1-enyl)butan-2-(R ,S)-ol; (S)-2 ,2-dimethyl-3-(4-(prop-1-en-2-yl)cyclohex-1-enyl)propanal; 3-cyclopropyl-2-(cyclo-propylmethyl)-2-methylpropanal; 3-cyclopropyl-2-(cyclopro-pylmethyl)-2-methylpropan-1-ol; (S)-2 ,2-dimethyl-3-(4-(prop-1-en-2-yl)cyclohex-1-enyl)propan-1-ol; (R ,S)-2 ,2-di(cyclohex-2-enyl)propanenitrile; 1-cyclopropyl-2-(cyclopropylme-thyl)-2 ,4-(R ,S)-dimethylhexan-3-one; 1-(1-(cyclopropyl-methyl)cyclopropyl)ethanone; 1-(1-(cyclopropylmethyl)-cyclopropyl)pentan-1-one; 2-methyl-2-((1R ,S)(5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-enyl)propanenitrile; 1-(1-(cyclopropylmethyl)-cyclopropyl)pentan-1-(R ,S)ol; 3-((1R ,5S)-6 ,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)propanenitrile; (2R ,S)-3-((1R ,5S)-6 ,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)-2-methylpropanenitrile; 1-(((1R ,5S)-6 ,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-yl)-methyl)cyclobutanecarbonitrile; 4-allyl-4-methylnon-1-en-5-one; 4-allyl-4-methylnon-1-en-5-(R ,S)-ol; iso-butyl 2 ,5-dimethylhex-4-enoate; 7-cyclopentylideneheptan-2-one; 8-cyclopentylideneoctan-3-one; (E/Z)-11-methyldodec-8-en-3-one (9:1—E:Z); (E/Z)-10- ...

Подробнее
04-02-2021 дата публикации

Organic Material for an Electronic Optoelectronic Device and Electronic Device Comprising the Organic Material

Номер: US20210036230A1
Принадлежит:

The present invention relates to an organic material and to an electronic device comprising the organic material, particularly to an electroluminescent device, particularly to an organic light emitting diode (OLED), wherein the semiconducting material comprises a multiple-substituted phenyl moiety, an aryl moiety with at least two fused rings, a polar moiety and optional linkers between these moieties. 2. The compound of claim 1 , wherein the compound has a dipole moment of about ≥0.6 Debye.3. The compound of claim 1 , wherein R is chosen so that the dipole moment of the compound R-phenyl is about ≥0.6 Debye.6. The compound of any of claim 1 ,wherein 1≤a+b+c+d+e≤4.7. The compound of claim 1 ,wherein 2≤a+b+c+d+e≤3.8. The compound of claim 1 ,{'sub': 2', '30, 'wherein R is selected from substituted or unsubstituted Cto Cheteroaryl group and CN'}10. The compound of claim 1 ,wherein n is 1 or 2.11. An electronic device comprising a first electrode claim 1 , a second electrode claim 1 , and arranged between the first and second electrode claim 1 , a layer comprising a compound according to .12. The electronic device of claim 1 , wherein the electronic device comprises a hole blocking layer comprising a compound according to .13. The electronic device of claim 1 , wherein the electronic device comprises an electron transport layer comprising a compound according to .14. The electronic device according to claim 11 , wherein the electronic device is an electroluminescent device.15. The electronic device according to claim 11 , wherein the electronic device is an organic light emitting diode.16. A display device comprising an electronic device according to .17. A display device according to claim 11 , wherein the display device comprises an organic light emitting diode according to . The present invention relates to an organic material and to an electronic device comprising the organic material, particularly to an electroluminescent device, particularly to an organic light ...

Подробнее
12-02-2015 дата публикации

ARYL SUBSTITUTED PROPENOIC AMIDES AND ESTERS

Номер: US20150044149A1
Принадлежит:

The present disclosure relates, according to some embodiments, to molecules, including substituted propenoic amides (e.g., aryl substituted propenoic amides), that may receive excited state energy from light-absorbing molecules. According to some embodiments, the present disclosure relates to molecules, including substituted propenoic amides (e.g., aryl substituted propenoic amides), that may quench, dissipate, and/or otherwise resolve excited state energy (e.g., as heat). 2. A composition according to claim 1 , wherein R1 is hydrogen and R1′ is a methoxyl group (—OCH).3. A composition according to claim 1 , wherein R1 is a methoxyl group (—OCH) and R1′ is hydrogen.4. A composition according to claim 1 , wherein at least one of R2 claim 1 , R2′ claim 1 , R3 claim 1 , R3′ claim 1 , R4 claim 1 , R4′ claim 1 , R5 claim 1 , and R5′ is an alkyl group having from about 1 to about 30 carbon atoms.5. A composition according to claim 1 , wherein at least one of R2 claim 1 , R2′ claim 1 , R3 claim 1 , R3′ claim 1 , R4 claim 1 , R4′ claim 1 , R5 claim 1 , and R5′ is alkoxyl.6. A composition according to claim 1 , wherein at least one of R2 claim 1 , R2′ claim 1 , R3 claim 1 , R3′ claim 1 , R4 claim 1 , R4′ claim 1 , R5 claim 1 , and R5′ is a substituted alkyl group.8. A paint claim 1 , a coating claim 1 , a cosmetic claim 1 , a sunscreen claim 1 , or a pharmaceutical comprising a composition according to .10. A substituted propenoic amide according to claim 9 , wherein R1 is hydrogen and R1′ is a methoxyl group (—OCH).11. A substituted propenoic amide according to claim 9 , wherein R1 is a methoxyl group (—OCH) and R1′ is hydrogen.12. A substituted propenoic amide according to claim 9 , wherein at least one of R2 claim 9 , R2′ claim 9 , R3 claim 9 , R3′ claim 9 , R4 claim 9 , R4′ claim 9 , R5 claim 9 , and R5′ is an alkyl group having from about 1 to about 30 carbon atoms.13. A substituted propenoic amide according to claim 9 , wherein at least one of R2 claim 9 , R2′ claim 9 ...

Подробнее
25-02-2016 дата публикации

Novel Intermediate Used for Preparing Tapentadol or Analogues Thereof

Номер: US20160052873A1
Принадлежит:

The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production. 2. The compound according to claim 1 , wherein Ris selected from F claim 1 , Cl claim 1 , Br claim 1 , CHF claim 1 , CF claim 1 , OH claim 1 , SOCH claim 1 , NH claim 1 , CN claim 1 , CHO claim 1 , —Calkyl claim 1 , —Calkoxyl claim 1 , —Ccycloalkyl claim 1 , —Calkylenephenyl claim 1 , —Calkylenenaphthyl claim 1 , tetrahydrofuran or —C(═O)Calkyl; and preferably selected from Cl claim 1 , methyl claim 1 , OH claim 1 , NHor methoxy.3. The compound according to claim 1 , wherein the compound is selected from the following compounds:2-methyl-3-(3-hydroxyphenyl)pentanenitrile; and2-methyl-3-(3-methoxyphenyl)pentanenitrile.5. The compound according to claim 1 , wherein the compound is an intermediate for preparing tapentadol and analogues thereof. This application is a division application of U.S. application Ser. No. 13/884,810 filed on May 10, 2013, which claims the priority right of PCT/CN 2011/001248 filed on Jul. 29, 2011.The invention belongs to the field of pharmaceutical preparation, and relates to a novel intermediate for preparing tapentadol and analogues thereof.Tapentadol hydrochloride is the hydrochloride of tapentadol, and a novel central analgesic with dual mechanism of action developed by Johnson & Johnson Inc. in USA. It is used as medicine in the form of single isomer of (1R,2R), molecular formula: CHClNO, chemical name: (1R,2R)-3-(3-dimethylamino ...

Подробнее
26-02-2015 дата публикации

Synthesis of Triethylenetetramines

Номер: US20150057466A1
Принадлежит: PHILERA NEW ZEALAND Ltd

Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.

Подробнее
15-05-2014 дата публикации

Substituted cathechols as inhibitors of il-4 and il-5 for the treatment bronchial asthma

Номер: US20140135393A1

The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.

Подробнее
01-03-2018 дата публикации

Methyl menthol derivative and cooling agent composition containing same

Номер: US20180057447A1
Принадлежит: Takasago International Corp

The purpose of the present invention is to provide a cooling agent composition containing a novel methyl menthol derivative having no undesirable feeling of stimulation, malodor, bitterness, or the like, it being possible to use the cooling agent composition as a cooling agent or sensory stimulation agent having exceptional persistence of a sense of coolness and refreshing feeling. The present invention pertains to a cooling agent composition containing a methyl menthol derivative represented by general formula (1A) or general formula (1B).

Подробнее
02-03-2017 дата публикации

Compound for organic photoelectric device and organic photoelectric device image sensor, and electronic device including the same

Номер: US20170062726A1

A compound for an organic photoelectric device includes at least one of a compound represented by Chemical Formula 1, a compound represented by Chemical Formula 2 and a combination thereof.

Подробнее
27-02-2020 дата публикации

Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity

Номер: US20200060995A1
Принадлежит:

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described. 3. The compound of claim 1 , wherein said compound is a mixture of enantiomers.4. The compound of claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 10%.5. The compound of claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 20%.6. The compound of claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 50%.7. The compound of claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 70%.8. The compound of claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 90%.9. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.10. A method of treating a disease or condition involving monoamine reuptake claim 1 , comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a compound of .11. The method of claim 10 , wherein the disease or condition is an anxiety disorder claim 10 , generalized anxiety disorder claim 10 , depression claim 10 , post-traumatic stress disorder claim 10 , obsessive-compulsive disorder claim 10 , panic ...

Подробнее
05-06-2014 дата публикации

MEROCYANINE DERIVATIVES

Номер: US20140150380A1
Принадлежит:

Disclosed are compounds of formula (1) and (2) and/or E/E-, E/Z- or Z/Z geometrical isomer forms thereof; wherein R1-R5, R1-R11 and A are defined as in description. The compounds are used as UV absorbers for protecting household products from photolytic and oxidative degradation, as plastic additives, preferably for food and pharmaceutical packaging applications, for preventing photo-degradation of food by incorporation of the compounds of formula (1′) and/or (2′) into transparent food containers, for protection of UV-A sensitive drugs from photo-degradation by incorporation of UV absorber in transparent blister foils or transparent pharmacy containers, as additives for photographic and printing applications, as additives for electronic applications and protecting the ingredients in agriculture applications. 4. Compounds of formula (1) according to claim 1 , wherein Ris C-Calkyl claim 1 , which is optionally substituted by one or more than one hydroxy.5. Compounds of formula (1) according to claim 1 , wherein{'sub': 6', '1', '12, 'Ris C-Calkyl which is substituted by one or more than one hydroxy;'}{'sub': 1', '2', '4', '22', '1', '2', '2', 'n, 'one of Rand Ris C-Calkyl; or Rand Rtogether with the nitrogen atom linking them form a —(CH)— ring which is optionally interrupted by —O— and/or —NH—; and'}{'sub': 4', '5, 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'Rand Rand n are defined as in .'}6. Compounds of formula (2) according to claim 1 , wherein{'sub': 11', '2', 'm', '12, 'Ris a radical of formula (1a) —(CH)—R, wherein'}{'sub': 12', '1', '12', '1', '6', '1', '6, 'Ris C-Calkyl; or C-Calkoxy-C-Calkyl;'}m is a number from 1 to 5; and{'sub': 7', '8', '9', '10, 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'R, R, R, Rand A are defined as in .'}7. Compounds according to claim 1 , wherein in formulas (1) and (2){'sub': 1', '2', '7', '8, 'Rand Rand Rand Rrespectively together with the linking nitrogen atom form a piperidyl radical or a morpholinyl radical.'}8. ...

Подробнее
16-03-2017 дата публикации

Novel gamma-aminobutyric acid (gaba) analogues for the treatment of pain and other disorders

Номер: US20170071909A1
Принадлежит: Novassay SA

A compound of Formula 1 wherein R 1 represents hydrogen, halo, a C1-C4 alkyl group, a C1-C4 alkylhalide group, a C1-C4 alkoxy-C2-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group or a C3-C7 cycloalkyl group; R 2 represents or a tautomer thereof; and R 3 represents hydrogen, a C1-C4 alkyl group, a C1-C4 alkoxy-C2-C4 alkyl group or a C3-C7 cycloalkyl group; or a pharmaceutically acceptable salt or solvate thereof. Processes to prepare said compounds and novel intermediates are also claimed. Such compound finds utility in treating neuropathic pain and disorders of the central nervous system.

Подробнее
07-03-2019 дата публикации

Triazoles as kv3 inhibitors

Номер: US20190071405A1

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.

Подробнее
07-03-2019 дата публикации

HOLE INJECTION LAYER AND CHARGE GENERATION LAYER CONTAINING A TRUXENE BASED COMPOUND

Номер: US20190074446A1
Автор: Xia Chuanjun
Принадлежит:

Hole injection layer and charge generation layer containing a truxene based compound are disclosed for organic electronic devices. By applying the truxene based compound for the hole injection layer, low driving voltage, high efficiency and long lifetime of the device can be achieved. In addition, a P-type charge generation layer comprising the truxene based compound can be used in tandem OLEDs structure and can further improve the voltage, efficiency and lifetime of the device. 2. The device of claim 1 , wherein the hole injection layer comprising the compound of formula 1 is in contact with the anode.3. The device of claim 1 , wherein R is selected from the group consisting of nitro claim 1 , fluorine claim 1 , cyano claim 1 , trifluoromethyl claim 1 , trifluoromethoxy claim 1 , and pentafluorosulfide.5. The device of claim 1 , wherein the hole injecting layer is a layer consisting entirely of the compound having formula 1.6. The device of claim 1 , wherein the hole injection layer further comprises an aromatic amine compound.9. The device of claim 8 , wherein R is selected from the group consisting of nitro claim 8 , fluorine claim 8 , cyano claim 8 , trifluoromethyl claim 8 , trifluoromethoxy claim 8 , and pentafluorosulfide.11. The device of claim 8 , wherein the charge generation layer is a layer consisting entirely of the compound having formula 1.12. The device of claim 8 , wherein the charge generation layer is a P-type charge generation layer.13. The device of claim 8 , wherein the charge generation layer further comprises an aromatic amine compound. This application claims the benefit of U.S. Provisional Application No. 62/553,919, filed Sep. 4, 2017, the entire content of which is incorporated herein by reference.The present invention relates to a hole injection layer and a charge generation layer for organic electronic devices, such as organic light emitting devices. More specifically, the present invention relates to a hole injection layer and a charge ...

Подробнее
18-03-2021 дата публикации

METHOD FOR MANUFACTURING AROMATIC NITRILE COMPOUND

Номер: US20210078940A1
Принадлежит: API Corporation

The present invention provides a method for industrially producing a highly pure aromatic nitrile compound and a highly pure aromatic carboxylic acid compound safely and highly efficiently at low costs. Compound (2) is subjected to Willgerodt reaction in the presence of an additive as necessary, and the obtained amide compound (3) is hydrolyzed and neutralized to give carboxylic acid compound (4). Carboxylic acid compound (4) is reacted with a halogenating agent in the presence of a catalyst as necessary in an organic solvent, and further reacted with an amidating agent, and the obtained amide compound (5) or (6) is reacted with a dehydrating agent to give nitrile compound (1). Alternatively, carboxylic acid compound (4) is reacted with a halogenating agent and a compound represented by the formula RSORin the presence of a catalyst as necessary in an organic solvent to give nitrile compound (1). Np is a naphthyl group optionally having substituent(s), Ris an alkylene group having 1-3 carbon atoms, and other symbols are as described in the DESCRIPTION. 2. The method for producing a nitrile compound according to claim 1 , wherein the aforementioned step 2B is the following step 2B-1 or step 2B-2: 'a step of reacting the carboxylic acid compound represented by the aforementioned formula (4) with a halogenating agent and a compound represented by the aforementioned formula (7) in the presence of a catalyst as necessary in an organic solvent at 80° C.-180° C. to give a nitrile compound represented by the aforementioned formula (1);', 'step 2B-1 'a step of reacting reaction starting material 1 which is a mixture of the carboxylic acid compound represented by the aforementioned formula (4), a halogenating agent, a first organic solvent and, where necessary, a catalyst, with reaction starting material 2 which is a mixture of a compound represented by the aforementioned formula (7) and a second organic solvent at 80° C.-180° C. to give a nitrile compound represented by the ...

Подробнее
15-03-2018 дата публикации

Oxocarbon-, Pseudooxocarbon- and Radialene Compounds and Their Use

Номер: US20180076389A1
Принадлежит:

The present invention relates to oxocarbon-, pseudooxocarbon- and radialene compounds as well as to their use as doping agent for doping an organic semiconductive matrix material, as blocker material, as charge injection layer, as electrode material as well as organic semiconductor, as well as electronic components and organic semiconductive materials using them. 2. Use according to claim 1 , characterized in that Y is perfluoroalkyl.3. Use according to claim 1 , characterized in that aryl is partially or completely fluorinated.4. Use according to claim 1 , characterized in that hetaryl is selected from pyridyl claim 1 , pyrimidyl claim 1 , triazine claim 1 , or oxadiazole.5. Use according to claim 1 , characterized in that R1-R8 are independently selected from perhalogenated and/or partially halogenated alkyl groups.7. Oxocarbon- claim 6 , pseudooxocarbon- and radialene compounds according to claim 6 , characterized in that hetaryl is selected from pyridyl claim 6 , pyrimidyl claim 6 , triazine claim 6 , or oxadiazole.8. Use of oxocarbon- claim 6 , pseudooxocarbon- and radialene compounds according to or their radical anionic salts claim 6 , dianionic salts or charge transfer complexes with donors as organic ferromagnets.9. Use of oxocarbon- claim 6 , pseudooxocarbon- and radialene compounds according to or their radical anionic salts claim 6 , dianionic salts or their charge transfer complexes with donors as organic conductors.10. Organic semiconductive material containing at least one organic matrix compound and one doping agent claim 1 , characterized in that the doping agent is one or more oxocarbon- claim 1 , pseudooxocarbon- or radialene compounds according to .11. Organic semiconductive material according to claim 10 , characterized in that the molar doping ratio of doping agent to matrix molecule and/or the doping ratio of doping agent to monomeric units of a polymeric matrix molecule is between 1:1 and 1:100 claim 10 ,000.12. Electronic component with an ...

Подробнее
24-03-2016 дата публикации

SHIP1 MODULATORS AND METHODS RELATED THERETO

Номер: US20160083387A1
Принадлежит:

Compounds of formula (I): where R, R, R, R, R, R, Rand Rare defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. 2. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is substituted with one hydrogen;{'sup': '5', 'C14 is substituted with one hydrogen when Ris not a direct bond to C14;'}C15 is substituted with two hydrogens;{'sup': 1', '8', '9', '8', '9, 'sub': '2', 'Ris —R—ORor —R—N(R);'}{'sup': 2', '8', '9', '8', '8', '9', '8', '9', '8', '9', '8', '9', '9, 'sub': 2', '2, 'Ris —R—OR, —R—CN, —R—C(O)OR, —R—C(O)N(R), —R—N(R), —R—N(R)C(O)R, optionally substituted heterocyclylalkyl or optionally substituted heteroarylalkyl;'}{'sup': 4a', '4b', '7', '3, 'sub': 2', '2', '2', '2', '3', '3, 'Ris hydrogen or alkyl, Ris a direct bond to the carbon to which Ris attached, and Ris —CHNHor —CHN(H)C(O)(CH)CH;'}{'sup': 5', '5, 'Ris alkyl or Ris a direct bond to C14;'}{'sup': '6', 'Ris hydrogen;'}{'sup': 7', '8', '9, 'Ris hydrogen or —R—OR;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain; and'}{'sup': '9', 'each Ris independently hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl.'}3. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two ...

Подробнее
24-03-2016 дата публикации

Cyanostilbenes

Номер: US20160083655A1
Принадлежит: ROLIC AG

The present invention relates to novel compounds that are particularly useful for the alignment, especially photoalignment, of slave material, especially liquid crystals for optical or electro-optical applications, such as security applications, liquid crystal devices or optical or electro-optical films.

Подробнее
23-03-2017 дата публикации

PROPELLANE DERIVATES AND SYNTHESIS

Номер: US20170081295A1
Автор: Bunker Kevin Duane
Принадлежит:

Disclosed herein are compounds of the general Formula (I), and methods of synthesizing substituted bicyclo[1.1.1 jpentanes. The synthetic methods described herein use a [1.1.1]propellane, a Group VIII transition metal compound, a hydride source and a reagent that can contribute a substituent to form a substituted bicyclo[1.1.1]pentane, such as a compound of the general Formula (I). 1. A method for preparing a substituted bicyclo[1.1.1]pentane compound comprising:combining [1.1.1]propellane;a Group VIII transition metal compound;a hydride source; anda reagent capable of contributing all or a part of a substituent group such that bicyclo[1.1.1]pentane is substituted with the substituent group.3. The method of claim 2 , wherein Ris —N claim 2 , halogen claim 2 , —CN claim 2 , —OH claim 2 , —SCN claim 2 , —NCO claim 2 , —NO claim 2 , —C(═NOR)(CN) claim 2 , —CH(═NOR) or —COH.4. The method of claim 2 , wherein Ris an optionally substituted Calkyl claim 2 , an optionally substituted Calkenyl claim 2 , an optionally substituted Calkynyl claim 2 , an optionally substituted cycloalkyl claim 2 , an optionally substituted cycloalkenyl claim 2 , an optionally substituted cycloalkynyl claim 2 , an optionally substituted aryl claim 2 , an optionally substituted heteroaryl claim 2 , an optionally substituted heterocyclyl claim 2 , an optionally substituted aryl(Calkyl) claim 2 , an optionally substituted heteroaryl(Calkyl) claim 2 , an optionally substituted heterocyclyl(Calkyl) claim 2 , an optionally substituted alkoxy claim 2 , an optionally substituted acyl claim 2 , an optionally substituted amino claim 2 , an optionally substituted alkoxyalkyl claim 2 , an optionally substituted acylalkyl claim 2 , an optionally substituted aminoalkyl claim 2 , an optionally substituted hydroxyalkyl claim 2 , an optionally substituted haloalkyl claim 2 , an optionally substituted haloalkoxy claim 2 , an optionally substituted arylthio claim 2 , or an optionally substituted alkylthio.5. The ...

Подробнее
29-03-2018 дата публикации

Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity

Номер: US20180085327A1
Принадлежит:

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described. 3. The compound of claim 1 , wherein said compound is a mixture of enantiomers.4. The compound of claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 10%.5. The compound of claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 20%.6. The compound of claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 50%.7. The compound of claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 70%.8. The compound of claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 90%. This application is a continuation of U.S. patent application Ser. No. 15/205,491, filed Jul. 8, 2016, which is a continuation of U.S. patent application Ser. No. 12/234,236, filed Sep. 19, 2008, now U.S. Pat. No. 9,422,225, which is a continuation of U.S. patent application Ser. No. 11/565,451, filed Nov. 30, 2006, now U.S. Pat. No. 7,456,317 issued Nov. 25, 2008, which claims priority to U.S. Provisional Patent Application Nos. 60/741,315, filed Dec. 1, 2005 and 60/841,366, filed Aug. 30, 2006, all of which are incorporated by reference in their ...

Подробнее
12-05-2022 дата публикации

COMPOUND

Номер: US20220144759A1
Принадлежит: Sumitomo Chemical Company, Limited

A compound having a molecular weight of 3000 or less and a partial structure represented by Formula (X) is provided: 3. The compound according to claim 2 , wherein at least one selected from Rand Ris a nitro group claim 2 , a cyano group claim 2 , a halogen atom claim 2 , —OCF claim 2 , —SCF claim 2 , —SF claim 2 , —SF claim 2 , a fluoroalkyl group claim 2 , a fluoroaryl group claim 2 , —CO—O—R claim 2 , —SO—R claim 2 , or —CO—R(Rrepresents a hydrogen atom claim 2 , an alkyl group having 1 to 25 carbon atoms which may have a substituent claim 2 , or an aromatic hydrocarbon group having 6 to 18 carbon atoms which may have a substituent).4. The compound according to claim 2 , wherein at least one selected from Rand Ris a nitro group claim 2 , a cyano group claim 2 , a fluorine atom claim 2 , a chlorine atom claim 2 , —OCF claim 2 , —SCF claim 2 , a fluoroalkyl group claim 2 , —CO—O—R claim 2 , or —SO—R(Rrepresents a hydrogen atom claim 2 , an alkyl group having 1 to 25 carbon atoms which may have a substituent claim 2 , or an aromatic hydrocarbon group having 6 to 18 carbon atoms which may have a substituent).5. The compound according to claim 2 , wherein at least one selected from Rand Ris a cyano group claim 2 , —CO—O—R claim 2 , or —SO—R(Rrepresents a hydrogen atom claim 2 , an alkyl group having 1 to 25 carbon atoms which may have a substituent claim 2 , or an aromatic hydrocarbon group having 6 to 18 carbon atoms which may have a substituent).6. The compound according to claim 2 , wherein at least one selected from Rand Ris a cyano group.7. The compound according to claim 2 , wherein Ris a cyano group claim 2 , Ris a cyano group claim 2 , —CO—O—R claim 2 , or —SO—R(Rrepresents a hydrogen atom claim 2 , an alkyl group having 1 to 25 carbon atoms which may have a substituent claim 2 , or an aromatic hydrocarbon group having 6 to 18 carbon atoms which may have a substituent).8. The compound according to claim 2 , wherein both Rand Rare a cyano group.9. The compound ...

Подробнее
12-05-2022 дата публикации

COMPOUND

Номер: US20220144769A1
Принадлежит:

A compound represented by Formula (I) is provided: 2. The compound according to claim 1 , wherein Ris a nitro group claim 1 , a cyano group claim 1 , —F claim 1 , —OCF claim 1 , —SCF claim 1 , —SF claim 1 , —SF claim 1 , —SO—R(Rrepresents a hydrogen atom claim 1 , an alkyl group having 1 to 25 carbon atoms which may have a substituent claim 1 , or an aromatic hydrocarbon group having 6 to 18 carbon atoms which may have a substituent) claim 1 , a fluoroalkyl group claim 1 , or a fluoroaryl group.3. The compound according to claim 1 , wherein Ris a cyano group.4. The compound according to claim 1 , wherein at least one selected from Rand Ris a cyano group claim 1 , a nitro group claim 1 , —OCF claim 1 , —SCF claim 1 , —SF claim 1 , —CO—O—R claim 1 , —SO—R(Rrepresents a hydrogen atom claim 1 , an alkyl group having 1 to 25 carbon atoms which may have a substituent claim 1 , or an aromatic hydrocarbon group having 6 to 18 carbon atoms which may have a substituent) claim 1 , a fluoroalkyl group claim 1 , or a fluoroaryl group.5. The compound according to claim 1 , wherein at least one selected from Rand Ris a cyano group.6. The compound according to claim 1 , wherein both Rand Rare a cyano group.7. The compound according to claim 1 , wherein Rand Rare each independently an aliphatic hydrocarbon group which may have a substituent.8. The compound according to claim 1 , wherein Rand Rare linked to each other to form a ring.9. The compound according to claim 8 , wherein the ring formed by linking Rand Rto each other is a ring having no unsaturated bond.11. The compound according to claim 10 , wherein the ring Whas a 5 to 7-membered ring structure.12. The compound according to claim 10 , wherein the ring Wis a 6-membered ring structure.13. The compound of claim 1 , wherein λ max≥370 nm claim 1 ,(λ max represents a maximum absorption wavelength [nm] of the compound represented by Formula (I)).14. The compound according to claim 1 , which satisfies Formula (B) claim 1 ,{'br': ...

Подробнее
14-04-2016 дата публикации

Synthesis of Triethylenetetramines

Номер: US20160102060A1
Принадлежит: PHILERA NEW ZEALAND Ltd

Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.

Подробнее
23-04-2015 дата публикации

TRIAZOLES AS KV3 INHIBITORS

Номер: US20150111910A1
Принадлежит: AUTIFONY THERAPEUTICS LIMITED

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders. 147.-. (canceled)50. The compound according to claim 48 , wherein ring A has one heteroatom.53. The compound according to claim 48 , wherein Ris H or methyl.54. The compound according to claim 48 , wherein Ris H claim 48 , methyl claim 48 , ethyl claim 48 , isopropyl claim 48 , tert-butyl claim 48 , cyclopropyl claim 48 , Cspiro carbocyclyl claim 48 , trifluoromethyl or 2 claim 48 ,2 claim 48 ,2-trifluorethyl.55. The compound according to claim 48 , wherein Ris H claim 48 , methyl claim 48 , ethyl claim 48 , tert-butyl claim 48 , cyclopropyl claim 48 , trifluoromethyl or 2 claim 48 ,2 claim 48 ,2-trifluorethyl.56. The compound according to claim 48 , wherein Ris absent.57. The compound according to claim 48 , wherein Ris H or absent.58. The compound according to claim 48 , wherein Ris H or is absent.60. The compound according to claim 48 , wherein X is CH.61. The compound according to claim 48 , wherein X is N.62. The compound according to claim 48 , wherein Y is N.63. The compound according to claim 48 , wherein Y is CRand Ris H.64. The compound according to claim 48 , wherein Ris H claim 48 , methyl or ethyl.65. A compound according to which is a compound of any one of Examples 1 to 54.66. A method for the prophylaxis or treatment of hearing disorders claim 48 , schizophrenia claim 48 , bipolar disorder claim 48 , sleep disorders or spinocerebellar ataxia by administering to a subject a compound according to .68. A derivative of a compound of formula (I) according to functionalised via the secondary nitrogen of the triazolone with a group L claim 48 , wherein L is selected from:{'sup': −', '+', '+, 'a) —PO(OH)O.M, wherein M is a pharmaceutically acceptable monovalent counterion,'}{'sup': −', '+, 'sub': '2', 'b) —PO(O).2M,'}{'sup': −', '2+', '2+, 'sub': '2', 'c) —PO(O).D, wherein D is a pharmaceutically ...

Подробнее
28-04-2016 дата публикации

Substituted 5-Hydroxy-2,3-Diphenylpentanonitrile Derivatives, Processes For Their Preparation And Their Use As Herbicides And/Or Plant Growth Regulators

Номер: US20160113277A1
Принадлежит:

Primarily, the present invention relates to the use of substances of the formula (I) as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants. The invention furthermore relates to the novel herbicidal substances of the formulae (Ib) and (Ia). The present invention also relates to corresponding compositions comprising one or more of the herbicides of the formula (I) and further agrochemically active substances, and also to plant growth-regulating or herbicidal compositions comprising one or more of these compounds. Moreover, the present invention relates to processes for preparing the compounds of the formula (I). 2. A compound according to claim 1 , wherein{'sup': '1', 'Rrepresents hydrogen or a hydrolyzable radical having a total of up to 30 carbon atoms, optionally a hydrolyzable radical having a total of 1 to 24 carbon atoms, optionally having a total of 1 to 20 carbon atoms.'}3. A compound according to claim 1 , wherein{'sup': 1', '1, 'claim-text': represents an optionally substituted hydrocarbon radical or an optionally substituted heterocyclyl radical, or', {'sup': a', 'b', 'c', 'a', 'b, 'represents a radical of the formula SiRRR, or —NRR,'}, {'sup': a', 'b', 'c', 'a', 'b, 'where each of the radicals Rand Rindependently of the other represents hydrogen or an optionally substituted hydrocarbon radical and Rindependently represents an optionally substituted hydrocarbon radical, or —NRRrepresents a 3- to 9-membered heterocycle which, in addition to this nitrogen atom, may contain one or two further ring heteroatoms from the group consisting of N, O and S and which is substituted or unsubstituted, or'}, {'sup': e', 'f', 'e', 'f, 'sub': 2', '1', '8', '1', '4', '2', '8', '2', '8', '1', '6', '1', '6', '1', '8', '1', '4', '1', '4', '1', '8', '3', '8', '3', '8', '1', '8', '3', '8', '3', '8', '1', '8', '1', '4', '1', '4', '1', '8', ...

Подробнее
03-05-2018 дата публикации

FTO Inhibitors

Номер: US20180118665A1
Автор: Huang Niu, Peng Shiming

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition. 2. The inhibitor or composition of wherein the heterocyclic C3-C18 hydrocarbyl comprises:a 3 membered ring that is an optionally substituted: aziridine, oxirane, oxaziridine;a 4 membered ring that is an optionally substituted: azetidine, oxetane, oxazetidine;a 5 membered ring that is an optionally substituted: pyrrole, 1,2-diazole (pyrazole), 1,3 diazole (imidazole), thiazole, isothiazole, oxazole, isoxazole, furan, dioxole, thiophene;a 6 membered ring that is an optionally substituted: pyridine, diazine, triazine, oxazine, thiazine, dioxine, oxathiine, dithiine;a 9 membered ring that is an optionally substituted: indole, benzothiazole, benzooxazole, benzofuran, benzodioxole, benzothiophene, benzodithiole; ora 10 membered ring that is an optionally substituted: quinoline, quinoxaline, quinazoline, chromene, benzodioxine, thiochromene, benzodithiine.3. The inhibitor or composition of wherein the optionally substituted claim 1 , optionally hetero- claim 1 , optionally cyclic C1-C18 hydrocarbyl in each instance is an optionally substituted C1-C9 alkyl claim 1 , C2-C9 alkenyl claim 1 , C2-C9 alkynyl claim 1 , or C5-C14 aryl hydrocarbon claim 1 , comprising 1-5 heteroatoms that are N claim 1 , S claim 1 , O or P claim 1 , including 1-5 nitrogen atoms claim 1 , or a heteroatom substituted with the hydrocarbon.4. The inhibitor or composition of wherein:one or both R1 and R2 is H;R3 is OH; and/orR is H or C1-C4 alkyl.6. The compound of claim 5 , wherein{'sub': '3', 'Ris OH;'}{'sub': 4', 'a', 'a', 'b', 'c, 'Ris heteroaryl, —COR, or —CONRR; ...

Подробнее
13-05-2021 дата публикации

N-TYPE SEMICONDUCTOR, AND ORGANIC PHOTOELECTRIC DEVICE, IMAGE SENSOR, AND ELECTRONIC DEVICE INCLUDING THE SAME

Номер: US20210143338A1
Принадлежит:

Disclosed are an n-type semiconductor including compound represented by Chemical Formula 1 or Chemical Formula 2, an image sensor, and an electronic device. 2. The n-type semiconductor of claim 1 , wherein L claim 1 , L claim 1 , and Lare independently a C1 to C30 alkylene group substituted with an electron withdrawing functional group claim 1 , a C2 to C30 alkenylene group substituted with an electron withdrawing functional group claim 1 , or a C2 to C30 alkynylene group substituted with an electron withdrawing functional group.3. The n-type semiconductor of claim 1 , wherein the electron withdrawing functional group is a halogen claim 1 , a C1 to C10 haloalkyl group claim 1 , a cyano group (—CN) claim 1 , a cyano-containing group claim 1 , a nitro group (—NO) claim 1 , a C1 to C10 carboxyl group claim 1 , a C2 to C30 N-containing heteroaryl group claim 1 , or a carbonyl group (—C(═O)R claim 1 , wherein R is a C1 to C10 alkyl group claim 1 , a C2 to C10 heteroalkyl group claim 1 , a C6 to C14 aryl group claim 1 , or a C2 to C10 heteroaryl group).5. The n-type semiconductor of claim 4 , wherein L claim 4 , L claim 4 , and Lare independently a C1 to C30 alkylene group substituted with an electron withdrawing functional group claim 4 , a C2 to C30 alkenylene group substituted with an electron withdrawing functional group claim 4 , or a C2 to C30 alkynylene group substituted with an electron withdrawing functional group.6. The n-type semiconductor of claim 4 , wherein the electron withdrawing functional group is a halogen claim 4 , a C1 to C10 haloalkyl group claim 4 , a cyano group (—CN) claim 4 , a cyano-containing group claim 4 , a nitro group (—NO) claim 4 , a C1 to C10 carboxyl group claim 4 , a C2 to C30 N-containing heteroaryl group claim 4 , or a carbonyl group (—C(═O)R claim 4 , wherein R is a C1 to C10 alkyl group claim 4 , a C2 to C10 heteroalkyl group claim 4 , a C6 to C14 aryl group claim 4 , or a C2 to C10 heteroaryl group.8. The n-type semiconductor of ...

Подробнее
27-05-2021 дата публикации

HNQO1-ACTIVATABLE FLUORESCENT PROBE FOR IMAGING CANCER CELLS IN-VITRO AND IN-VIVO

Номер: US20210154330A1
Принадлежит:

The present invention includes a probe, an assay, a method of detecting, a human NAD(P)H quinone oxidoreductase-1 (hNQO1) enzyme activity with a fluorescent probe comprising a quinone propionic acid (QPA) conjugated to dicyanoisophorone (DCP), wherein the hNQO1 reduces the probe to releases a fluorescent DCP, and a method of making the same. 1. An assay to detect human NAD(P)H quinone oxidoreductase-1 (hNQO1) enzyme activity comprising:contacting an hNQO1 enzyme with a probe comprising a quinone propionic acid (QPA) conjugated to dicyanoisophorone (DCP), wherein the hNQO1 reduces the probe releases a fluorescent DCP.2. The assay of claim 1 , wherein the probe is defined as further comprising an ester or amide bond between the QPA and the DCP.3. The assay of claim 1 , wherein the probe has at least one of: a large stokes shift claim 1 , a high sensitivity and selectivity against hNQO1 claim 1 , a low cytotoxicity claim 1 , or cell permeability.5. The assay of claim 1 , wherein a redox activity of hNQO1 reduces a quinone moiety of QPA into an o-hydroxydihydrocinnamic acid derivative that undergoes lactonization under physiological conditions to yield dihydrocoumarin and fluorescent DCP.6. The assay of claim 1 , wherein the hNQO1 enzyme is in a cell claim 1 , a tissue claim 1 , an organ claim 1 , or a cancer.7. The assay of claim 1 , wherein the hNQO1 enzyme is in a breast claim 1 , lung claim 1 , prostate claim 1 , stomach claim 1 , colon claim 1 , pancreatic claim 1 , brain claim 1 , or head and neck cancer.8. A probe comprising a quinone propionic acid (QPA) conjugated to a dicyanoisophorone (DCP).9. The probe of claim 8 , wherein the quinone propionic acid (QPA) is conjugated to the dicyanoisophorone (DCP) by an ester or amide bond.11. The method of claim 8 , wherein the probe has at least one of: a large stokes shift claim 8 , a high sensitivity and selectivity against hNQO1 claim 8 , a low cytotoxicity claim 8 , or cell permeability.12. The probe of claim 8 , ...

Подробнее
25-08-2022 дата публикации

P-TYPE DOPANT AND ORGANIC LIGHT EMITTING DIODE

Номер: US20220271232A1
Автор: LUO Jiajia
Принадлежит:

A P-type dopant is provided, which is a planar aromatic compound having different numbers of fluorine atoms and cyano groups connected at a periphery thereof, and allows adjustment of highest occupied molecular orbital (HOMO) energy levels and lowest unoccupied molecular orbital (LUMO) energy levels and effectively increases luminous efficiency of a light emitting layer. Moreover, an organic light emitting diode is disclosed, including an anode, a cathode, and a light emitting structure located between the anode and the cathode, wherein a hole injecting layer of the light emitting structure is a hole injecting layer including the P-type dopant described above. 11. The organic light emitting diode according to , wherein the organic light emitting diode further comprises an anode , a cathode , and a light emitting structure located between the anode and the cathode , wherein the light emitting structure comprises the hole injecting layer according to .12. The organic light emitting diode according to claim 11 , wherein the light emitting structure comprises the hole injecting layer claim 11 , a hole transporting layer claim 11 , an electron blocking layer claim 11 , a light emitting layer claim 11 , a hole blocking layer claim 11 , an electron transporting layer claim 11 , and an electron injecting layer which are sequentially formed. The present invention relates to the technical field of organic light emitting material, and more particularly, to a P-type dopant and an organic light emitting diode fabricated by using the P-type dopant.Organic light emitting diodes (OLEDs) have broad application prospects in fields of solid state lighting and flat panel displays, and light emitting materials are main factors affecting light emitting efficiency of organic light emitting diodes. In early days, light emitting guest materials used in organic light emitting diodes were fluorescent materials, having a ratio of singlet exciton and triplet excitons in an organic light ...

Подробнее
10-05-2018 дата публикации

METHODS FOR MULTI-DOSE SYNTHESIS OF [F-18]FDDNP FOR CLINICAL SETTINGS

Номер: US20180127355A1

A method of manufacturing 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)-malononitrile ([F-18]FDDNP) utilizes a semi-automated module that is used to perform fluorination, pre-purification, separation, product extraction, and formulation. The method is able to produce [F-18]FDDNP with high yields and ready for human administration under existing FDA regulations, and without the need for hazardous organic solvents such as dichloromethane (DCM), methanol (MeOH), and tetrahydrofuran (THF). The method also improves the speed with which [F-18]FDDNP can be synthesized with the method being able to generate a final product within about 90 to 100 minutes. This synthesis method is easily adaptable to FDA registered and approved automated synthesis systems. 1. A method of manufacturing 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)-malononitrile ([F-18]FDDNP) comprising:trapping [F-18]fluoride ion in a resin cartridge;eluting the [F-18]fluoride ion into a reaction vessel having a cryptand solution contained therein by passing a potassium salt solution followed by water through the resin cartridge, wherein a [F-18]fluoride/cryptand complex is formed therein;subjecting the [F-18]fluoride/cryptand complex to multiple rounds of azeotropic evaporation with anhydrous acetonitrile to form dried [F-18]fluoride ion/cryptand complex residue in the reaction vessel;reacting the dried [F-18]fluoride ion/cryptand complex with tosyloxy precursor 2-{[6-(2,2-dicyano-1-methylvinyl)-2-naphthyl](methyl)amino}ethyl-4-methylbenzenesulfonate (DDNPTs) in anhydrous acetonitrile to form a reaction product;passing the reaction product through an alumina cartridge and into an injection vessel;injecting the reaction product contained in the injection vessel to an HPLC column;collecting a fraction containing [F-18]FDDNP from the HPLC column in a dilution vessel;diluting the collected [F-18]FDDNP contained in the dilution vessel with water;passing the diluted [F-18 ...

Подробнее
10-05-2018 дата публикации

ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE

Номер: US20180130968A1
Автор: Ikeda Takeshi
Принадлежит: IDEMITSU KOSAN CO., LTD.

An organic electroluminescence device includes: an anode; a cathode; an emitting layer disposed between the anode and the cathode; and a hole transporting layer disposed between the anode and the emitting layer. The emitting layer contains a first compound represented by a formula (1) and a fluorescent second compound. The hole transporting layer contains a third compound represented by a formula (3). In the formula (1), Zis represented by a formula (1a). A cyclic structure represented by a formula (1b) or (1c) may be fused to Z. Each of Xand Xis an oxygen atom, a sulfur atom, NRor CRR. 2. The organic electroluminescence device according to claim 1 , wherein Xis an oxygen atom.3. The organic electroluminescence device according to claim 1 , wherein each of Xand Xis an oxygen atom.4. The organic electroluminescence device according to claim 1 , wherein{'sub': 111', '112', '112', '113', '113', '114', '115', '116', '116', '117', '117', '118, 'at least one of the pair of Rand R, the pair of Rand R, the pair of Rand R, the pair of Rand R, the pair of Rand Ror the pair of Rand Rare both substituents, and'}{'sub': 111', '112', '112', '113', '113', '114', '115', '116', '116', '117', '117', '118, 'at least one of the pair of Rand Rboth being the substituents, the pair of Rand Rboth being the substituents, the pair of Rand Rboth being the substituents, the pair of Rand Rboth being the substituents, the pair of Rand Rboth being the substituents or the pair of Rand Rboth being the substituents are bonded to each other to form a ring represented by the formula (1b) or (1c).'}7. The organic electroluminescence device according to claim 1 , wherein xin the first compound is 1.8. The organic electroluminescence device according to claim 1 , wherein xin the first compound is 1 or 2.9. The organic electroluminescence device according to claim 1 , wherein Lin the first compound is bonded to R.10. The organic electroluminescence device according to claim 1 , wherein Lin the first ...

Подробнее
01-09-2022 дата публикации

LIGHT-EMITTING DEVICE INCLUDING FUSED CYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE FUSED CYCLIC COMPOUND

Номер: US20220278295A1
Принадлежит:

A light-emitting device having a fused cyclic compound includes: a first electrode; a second electrode facing the first electrode; an interlayer between the first electrode and the second electrode and including an emission layer; and a fused cyclic compound of Formula 1: 2. The light-emitting device of claim 1 , wherein the first electrode comprises an anode claim 1 ,the second electrode comprises a cathode,the first layer comprising an interlayer that further includes a hole transport region between the first electrode and the second layer comprising an emission layer, and an electron transport region between the second layer comprising emission layer and the second electrode,the hole transport region includes a hole injection layer, a hole transport layer, an emission auxiliary layer, an electron blocking layer, or any combination thereof, andthe electron transport region includes a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.3. The light-emitting device of claim 1 , wherein the second layer comprises an emission layer that includes the fused cyclic compound of Formula 1.4. The light-emitting device of claim 3 , wherein the fused cyclic compound included in the emission layer is a condensed cyclic compound comprising a delayed fluorescence emitter claim 3 , andthe emission layer is configured to emit delayed fluorescence.5. The light-emitting device of claim 3 , wherein the emission layer is configured to emit blue light.6. The light-emitting device of claim 3 , wherein the emission layer further includes a host claim 3 , andthe fused cyclic compound included in the emission layer is a dopant, andthe amount of the host included in the emission layer is greater than the amount of the fused cyclic compound included in the emission layer.7. The light-emitting device of claim 1 , further comprising a capping layer located outside the first electrode or outside the second electrode claim 1 , whereinthe ...

Подробнее
19-05-2016 дата публикации

Battery

Номер: US20160141622A1
Принадлежит:

The present invention relates to a battery that includes at least one electrochemical cell. The at least one electrochemical cell includes a first electrode, a second electrode, a first electroactive material, a second electroactive material, and an electrolyte which is in contact with both electrodes, and at least one of the first electroactive material and the second electroactive material includes a radialene compound. Also provided is an electroactive material as well as a radialene compound. 1. A battery comprising at least one electrochemical cell , the at least one electrochemical cell comprising a first electrode , a second electrode , a first electroactive material , a second electroactive material , and an electrolyte , wherein the electrolyte is in contact with both electrodes , and at least one of the first electroactive material and the second electroactive material comprises a radialene compound.2. The battery according to claim 1 , wherein the first electroactive material comprises the radialene compound claim 1 , and is disposed in a first compartment of the electrochemical cell claim 1 , the first compartment comprising the first electrode claim 1 , which is electrically connected with the positive pole of the battery.3. The battery according to claim 1 , wherein the radialene compound comprises a carbocyclic core substituted with one or more groups independently selected from oxo claim 1 , imino claim 1 , or methylidene claim 1 , wherein the imino and methylidene groups are substituted with one or more electron withdrawing substituents.4. The battery according to claim 3 , wherein the one or more electron withdrawing substituents are cyano groups.6. The battery according to claim 5 , wherein at least one of Zand Z claim 5 , and at least one Zis dicyanomethylidene.7. The battery according to claim 5 , wherein one or two of Z claim 5 , Z claim 5 , and Zare oxo groups.8. The battery according to claim 1 , wherein the electrolyte comprises alkali metal ...

Подробнее
07-08-2014 дата публикации

TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE

Номер: US20140221384A1
Принадлежит: ERIMOS PHARMACEUTICALS LLC

The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers. 2. A composition comprising the BB-N compound of and a pharmaceutically acceptable carrier claim 1 , optionally with other pharmaceutically acceptable excipients.3. A method of administering to a subject an amount of the BB-N compound of alone or as part of a pharmaceutical composition effective prophylactically or for treating a viral infection.4. A method of administering to a subject an amount of the BB-N compound of alone or as part of a pharmaceutical composition effective prophylactically or for treating a proliferative disease.5. A method of administering to a subject an amount of the BB-N compound of alone or as part of a pharmaceutical composition effective prophylactically or for treating an inflammatory disease.6. A method of administering to a subject an amount of the BB-N compound of alone or as part of a pharmaceutical composition effective prophylactically or for treating a metabolic disease.7. A method of administering to a subject an amount of the BB-N compound of alone or as part of a pharmaceutical composition effective prophylactically or for treating a vascular disease.8. A kit comprising a pharmaceutical composition comprising the BB-N compound of and instructions for its use prophylactically or for treating at least one of a viral ...

Подробнее
08-09-2022 дата публикации

High purity 2-naphthylacetonitrile and method for producing same

Номер: US20220281806A1
Принадлежит: API Corp

The present invention provides high purity 2-naphthylacetonitrile with fewer impurities that is useful as a starting material or intermediate for the synthesis of various pharmaceutical products, agricultural chemicals, and chemical products, and a production method thereof. A high purity 2-naphthylacetonitrile having an HPLC purity of 2-naphthylacetonitrile of not less than 95 area %, and containing naphthalene compounds represented by the formulas (a)-(j) at a content of a predetermined area % or below. A method for producing high purity 2-naphthylacetonitrile, including the following step 1 and step 2: step 1: a step of subjecting 2′-acetonaphthone to a Willgerodt reaction in the presence of an additive where necessary, and hydrolyzing the obtained amide compound to give 2-naphthylacetic acid; step 2: a step of reacting the 2-naphthylacetic acid obtained in step 1, a halogenating agent and sulfamide in the presence of a catalyst as necessary in an organic solvent to give 2-naphthylacetonitrile.

Подробнее
08-09-2022 дата публикации

PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE

Номер: US20220281835A1
Принадлежит:

Phenol derivatives of general formula (I) and (II), wherein meanings of the substituents are indicated in the description, their pharmaceutically acceptable salts, together with the processes for their preparation, their use as antimicrobial, antibacterial, bactericide agents and the corresponding pharmaceutical compositions are disclosed. 4: A compound as set forth in claim 1 , formulated as a medicament.5: A compound as set forth in claim 1 , formulated as antimicrobial and/or antibacterial and/or bactericide.7: A pharmaceutical composition comprising: (a) at least one compound of as an active ingredient; and (b) a pharmaceutically acceptable adjuvant claim 1 , a vehicle or an excipient.8: A method for treating a microbial infection comprising administering to an individual in need thereof a compound as set forth in .9: A method for treating a microbial infection comprising administering to an individual in need thereof a compound as set forth in .10: A method for treating a microbial infection comprising administering to an individual in need thereof a compound as set forth in .11: A method for treating a microbial infection comprising administering to an individual in need thereof a compound as set forth in .12: The method of claim 8 , wherein the microbial infection is a bacterial claim 8 , viral claim 8 , fungal claim 8 , protozoal or parasite infection.13: The method of claim 12 , wherein the bacterial infection is a gram-positive or a gram-negative bacterial infection.14Staphylococcus aureus, Enterococcus faecalis, Escherichia coliStreptococcus thermophilus.: The method of claim 13 , wherein the gram-positive or a gram-negative bacterial infection is an infection caused by a: claim 13 , or15: The method of claim 9 , wherein the microbial infection is a bacterial claim 9 , viral claim 9 , fungal claim 9 , protozoal or parasite infection.16: The method of claim 15 , wherein the bacterial infection is a gram-positive or a gram-negative bacterial infection. ...

Подробнее
26-05-2016 дата публикации

3-ARYL PROPIOLONITRILE COMPOUNDS FOR THIOL LABELING

Номер: US20160145199A1
Принадлежит:

The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile linkers. 7. Compound according to claim 6 , wherein the compound of interest is a biomolecule claim 6 , wherein the biomolecule is an antibody or a protein. The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile linkers.Over 90% of the human proteins contain cysteines, while in silico digest of the human proteome revealed that only about 15% of all human tryptic peptides detectable by mass spectroscopy (MS) contain at least one cysteine in their sequence. This observation combined with the presence of a highly reactive thiol group on its side chain makes cysteine an attractive target for chemical labeling. Cysteine is the only coded amino acid that carries a nucleophilic sulfhydryl (or thiol) group (—SH), which largely exceeds the reactivity of any other nucleophilic function susceptible to be present in proteins. As a result, chemospecific cysteine derivatization is by far the most widely used method for chemical tagging of proteins. Among the vast number of chemical cysteine modification methods reported in literature so far, reagents such as N-substituted maleimides, 4-vinylpyridines and iodoacetamides are most commonly used. All of them possess drawbacks preventing them from being ideal methodology for cysteine labeling, though being suited for this task. These drawbacks are mainly presence of undesired side reactions, in particular for iodoacetamides and maleimides, and instability of addition product in biological environments due to reversible thiol exchange and other side reactions.The present invention relates to a process for labeling compounds ...

Подробнее
25-05-2017 дата публикации

TRIPHENYLETHYLENE COMPOUNDS AND USES THEREOF

Номер: US20170144975A1
Принадлежит:

Triphenylethylene compounds as dual aromatase inhibitors and selective estrogen receptors modulators are described. Also described are methods for treating patients of breast cancers, and patients of breast cancer comorbid with osteoporosis, using the described triphenylethylence compounds or pharmaceutical formulations thereof. 8. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , hydrate claim 1 , or solvate thereof claim 1 , and one or more pharmaceutically acceptable carriers claim 1 , diluents claim 1 , and excipients.9. A method for treating a patient with cancer claim 8 , the method comprising the step of administering a therapeutically effective amount of the pharmaceutical composition of to the patient in need of relief from said cancer.10. The method of claim 9 , wherein the cancer patient is a patient of breast cancer.11. The method of claim 9 , wherein the cancer patient is a patient of breast cancer comorbid with osteoporosis.12. A method for treating a patient with cancer claim 1 , the method comprising the step of administering a therapeutically effective amount of a compound of claim 1 , together with one or more pharmaceutically acceptable carriers claim 1 , diluents claim 1 , and excipients claim 1 , to the patient in need of relief from said cancer.13. The method of claim 12 , wherein the cancer patient is a patient of breast cancer.14. The method of claim 12 , wherein the cancer patient is a patient of breast cancer comorbid with osteoporosis15. A method for treating a patient with cancer claim 1 , the method comprising the step of administering a therapeutically effective amount of a compound of claim 1 , together with a therapeutically effective amount of one or more other compounds of the same or different mode of action and one or more pharmaceutically acceptable carriers claim 1 , diluents claim 1 , and excipients claim 1 , to the patient in need of relief from said cancer.16. The ...

Подробнее
31-05-2018 дата публикации

ANTICONVULSANT COMPOUNDS

Номер: US20180148405A1
Принадлежит:

The present application relates to compounds and methods for reducing the severity of convulsant activity, or epileptic seizures. 2. The method of claim 1 , wherein R═H claim 1 , CH claim 1 , Cto C(linear or branched) claim 1 , cCH claim 1 , cCH claim 1 , or cCH.3. The method of claim 2 , wherein R═H or CH.4. The method of claim 3 , wherein R═H claim 3 , CH claim 3 , or Cto C(linear or branched).5. The method of claim 4 , wherein R═H or CH.7. The method of claim 1 , wherein the compound represented by the formula (I) is 2-(3 claim 1 ,5 claim 1 ,5-trimethylcyclohex-2-en-1-ylidene)pentanenitrile.8. The method of claim 1 , wherein the compound represented by the formula (I) is 3-methyl-2-(3 claim 1 ,5 claim 1 ,5-trimethylcyclohex-2-en-1-ylidene)butanenitrile. The present invention relates to compounds with anti-convulsant and pain activity. These compounds are useful in modulating voltage-gated sodium channel activity and are thus useful in the treatment of epilepsy and chronic or acute pain.Anti-convulsant compounds are presently in wide use in the treatment of a variety of conditions and diseases, including epilepsy. Epilepsy is a neurological condition which affects the nervous system and causes individuals with epilepsy to suffer from seizures. These seizures are caused by disruptions in the electrical communication between neurons in the brain. Epilepsy can be conceptualized as brain activity that is inappropriately synchronous. Seizures are often seen in electro encephalograms (EEGs) as high amplitude neural discharges that occur across brain regions. This brain activity is accompanied by behavioral disturbances that include loss of balance, jerking muscle movement, visual disturbances, and loss of consciousness. It is estimated that about 0.5% of the world's population has some form of epilepsy. Epilepsy is a lifelong condition, has a very low reversion rate, and is only rarely fatal. Persons with uncontrolled epilepsy are often under or un-employed.The ...

Подробнее
17-06-2021 дата публикации

METHODS AND COMPOSITIONS FOR TERPENOID TRICYCLOALKANE SYNTHESIS

Номер: US20210179546A1
Принадлежит:

In one aspect, the disclosure relates to methods for preparation of intermediates useful for the preparation of terpenoid cores. In a further aspect, the disclosed methods pertain to the preparation of compounds comprising a terpenoid core or scaffold, such as 6/7/5 tricycloalkanes. The disclosed methods utilize abundant starting materials and simple reaction sequences that can be used to tunably and scalably assemble common terpenoid cores. In various aspects, the present disclosure pertains to compounds prepared using the disclosed methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. 2. The compound of claim 1 , wherein E is —(C═O)OCH.3. The compound of claim 1 , wherein each of R claim 1 , R claim 1 , R claim 1 , and Ris independently hydrogen claim 1 , methyl claim 1 , phenyl claim 1 , or —CH(C═O)OCH.4. The compound of claim 1 , wherein each of Rand Rare hydrogen; and wherein Rand Rare covalently bonded and claim 1 , together with more intermediate carbons claim 1 , comprise —CHCH— or —CH═CH—.5. The compound of claim 11 , wherein Ris hydrogen claim 11 , methyl claim 11 , phenyl claim 11 , or —H(C═O)OCH.6. The compound of claim 11 , wherein Ais —CH— claim 11 , —CHCH claim 11 , —CH(C═O)OCHCH claim 11 , or —N(C═O)OC(CH).8. The compound of claim 7 , wherein E is —CN or —(C═O)OCH.9. The compound of claim 7 , wherein E is —CN.10. The compound of claim 7 , wherein each of R claim 7 , R claim 7 , R claim 7 , and Ris independently hydrogen claim 7 , methyl claim 7 , phenyl claim 7 , or —CH(C═O)OCH.11. The compound of claim 7 , wherein each of Rand Rare hydrogen; and wherein Rand Rare covalently bonded and claim 7 , together with more intermediate carbons claim 7 , comprise —CHCH— or —CH═CH—.12. The compound of claim 7 , wherein Ris hydrogen claim 7 , methyl claim 7 , phenyl claim 7 , or —CH(C═O)OCH.13. The compound of claim 7 , wherein Ais —N(C═O)OC(CH).15. The ...

Подробнее
02-06-2016 дата публикации

Organic light emitting display device

Номер: US20160155950A1
Принадлежит: LG Display Co Ltd

An organic light emitting display device is disclosed. The organic light emitting device includes a first light emitting part between an anode and a cathode, the first light emitting layer having a hole injection layer, a first hole transport layer, and a first light emitting layer; a second light emitting part over the first light emitting part, the second light emitting part having a second hole transport layer and a second light emitting layer; and a first charge generation layer between the first light emitting part and the second light emitting part, the first charge generation layer having a P-type charge generation layer, wherein at least one among the hole injection layer, the first hole transport layer, the second hole transport layer, and the P-type charge generation layer includes a carbonitrile compound.

Подробнее
07-06-2018 дата публикации

Phthalonitrile compound

Номер: US20180155276A1
Принадлежит: LG Chem Ltd

The present application can provide a phthalonitrile compound and a use thereof. The present application can provide a phthalonitrile compound capable of forming a phthalonitrile resin by self-curing or of serving as a curing agent after being mixed with another phthalonitrile compound, and a use of the phthalonitrile compound. The phthalonitrile compound can form a phthalonitrile resin by rapid self-curing even at a low temperature and does not create any defects resulting from the use of a conventional curing agent. Also, the phthalonitrile compound can be applied as a curing agent after being mixed with another compound, in which case, even if the content of the compound applied as a curing agent increases, the total content of the phthalonitrile resin obtained does not decrease, and thus a resin exhibiting an excellent degree of cure can be provided.

Подробнее
07-06-2018 дата публикации

SHIP1 MODULATORS AND METHODS RELATED THERETO

Номер: US20180155359A9
Принадлежит:

Compounds of formula (II): 3. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each independently hydrogen, alkyl, alkenyl or alkynyl;'}{'sup': 4a', '4b', '7, 'or Ris hydrogen, alkyl, alkenyl or alkynyl and Ris a direct bond to the carbon to which Ris attached;'}{'sup': 5', '5, 'Ris alkyl or Ris a direct bond to the carbon at C14;'}{'sup': 6', '8', '9', '8', '9, 'sub': '2', 'Ris hydrogen, —R—ORor —R—N(R);'}{'sup': 7', '8', '9', '8', '9', '7', '4b', '7, 'sub': '2', 'Ris hydrogen, —R—OR, —R—N(R), or a direct bond to C15, provided that when Ris a direct bond to C15, Ris not a direct bond to the carbon to which Ris attached;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain;'}{'sup': '9', 'each Ris hydrogen, alkyl, optionally substituted aryl and optionally substituted aralkyl;'}{'sup': '9a', 'each Ris hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl; optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;'}{'sup': '11', 'Ris optionally substituted heteroaryl; and'}{'sup': '12', 'Ris optionally substituted heterocyclyl.'}4. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each alkyl;'}{'sup': '5', 'Ris a direct bond to the carbon at C14;'}{'sup': '6', 'Ris hydrogen;'}{'sup': '7', 'Ris hydrogen;'}{'sup ...

Подробнее
14-05-2020 дата публикации

FTO Inhibitors

Номер: US20200148628A1
Автор: Huang Niu, Peng Shiming

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition. 4. The composition of wherein:R1 and R2 are independently H or Me;R3 is H, OH or NHR, wherein R is H or C1-C4 alkyl; andR4 is optionally substituted, heterocyclic C3-C18 hydrocarbyl comprising an n-membered ring wherein n=3-18, including 1 to n−1 heteroatoms independently selected from N, O, S and P.5. The composition of wherein the heterocyclic C3-C18 hydrocarbyl is:a 3 membered ring that is an optionally substituted aziridine, oxirane or oxaziridine;a 4 membered ring that is an optionally substituted azetidine, oxetane or oxazetidine;a 5 membered ring that is an optionally substituted pyrrole, 1,2-diazole (pyrazole), 1,3 diazole (imidazole), thiazole, isothiazole, oxazole, isoxazole, furan, dioxole or thiophene;a 6 membered ring that is an optionally substituted pyridine, diazine, triazine, oxazine, thiazine, dioxine, oxathiine or dithiine;a 9 membered ring that is an optionally substituted indole, benzothiazole, benzooxazole, benzofuran, benzodioxole, benzothiophene or benzodithiole; ora 10 membered ring that is an optionally substituted quinoline, quinoxaline, quinazoline, chromene, benzodioxine, thiochromene or benzodithiine.6. The composition of wherein the heterocyclic C3-C18 hydrocarbyl is:a 4 membered ring that is an optionally substituted azetidine, oxetane or oxazetidine.7. The composition of wherein the heterocyclic C3-C18 hydrocarbyl is:a 5 membered ring that is an optionally substituted pyrrole, 1,2-diazole (pyrazole), 1,3 diazole (imidazole), thiazole, isothiazole, oxazole, isoxazole, furan, dioxole or thiophene.8. ...

Подробнее
14-05-2020 дата публикации

Synthesis of Triethylenetetramines

Номер: US20200148647A1
Принадлежит:

Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity. 1. A method of treating a cardiovascular disorder in a subject in need thereof , the method comprising administering a triethylenetetramine salt that has a purity of greater than about 95% pure.2. The method of wherein the cardiovascular disorder is selected from the group comprising atherosclerosis; peripheral vascular disease; cardiovascular disease; heart disease; coronary heart disease; restenosis; angina; ischemia; heart failure; stroke; cardiomyopathy; pre-hypertension claim 1 , hypertension claim 1 , secondary hypertension claim 1 , malignant hypertension claim 1 , isolated systolic hypertension claim 1 , and portal hypertension; acute coronary syndromes claim 1 , including myocardial infarction; and vascular occlusive disorders.3. The method of wherein the cardiovascular disorder is cardiomyopathy.4. The method of wherein the cardiovascular disorder is selected from the group comprising diseases or disorders associated with a hypercoagulable state or protein C deficiency claim 1 , including but not limited to arterial thrombosis claim 1 , arterial embolism claim 1 , pulmonary embolism claim 1 , deep venous thrombosis claim 1 , venous thrombosis claim 1 , renal vein thrombosis claim 1 , mesenteric vein thrombosis claim 1 , atheroembolic renal disease claim 1 , thrombophlebitis claim 1 , heart attack or angina claim 1 , viral hemorrhagic fever claim 1 , disseminated intravascular coagulation claim 1 , purpura fulminans claim 1 , bone marrow and other transplantations claim 1 , severe burns claim 1 , major surgery claim 1 , severe trauma claim 1 , adult respiratory distress syndrome claim 1 , postphlebic syndrome claim 1 , coumarin-induced skin necrosis; thrombotic diseases claim 1 , disorders or conditions; sepsis and related diseases claim 1 , disorders or ...

Подробнее
14-05-2020 дата публикации

Oxocarbon-, Pseudooxocarbon- and Radialene Compounds and Their Use

Номер: US20200152873A1
Принадлежит:

The present invention relates to oxocarbon-, pseudooxocarbon- and radialene compounds as well as to their use as doping agent for doping an organic semiconductive matrix material, as blocker material, as charge injection layer, as electrode material as well as organic semiconductor, as well as electronic components and organic semiconductive materials using them. 2. The electronic component as claimed in claim 1 , wherein Y is perfluoroalkyl.3. The electronic component as claimed in claim 2 , wherein the perfluoroalkyl is CF.4. The electronic component as claimed in claim 1 , wherein the aryl is partially or completely fluorinated.5. The electronic component as claimed in claim 1 , wherein the hetaryl is selected from pyridyl claim 1 , pyrimidyl claim 1 , triazine claim 1 , or oxadiazole.6. The electronic component as claimed in claim 1 , wherein R-Rare independently selected from perhalogenated and/or partially halogenated alkyl groups.7. The electronic component as claimed in claim 6 , wherein R-Rare independently selected from perfluorinated alkyl groups.8. The electronic component as claimed in claim 1 , in the form of an organic light emitting diode claim 1 , a photovoltaic cell claim 1 , an organic solar cell claim 1 , an organic diode claim 1 , or an organic field effect transistor.9. The electronic component as claimed in claim 1 , wherein hetaryl is the substituted or unsubstituted aromatic heterocyclic compound or biheteroaryl claim 1 , and hetaryl is electron-deficient. This application is a divisional of U.S. patent application Ser. No. 15/817,398, filed Nov. 20, 2017, which is a divisional of U.S. patent application Ser. No. 14/570,443, filed Dec. 15, 2014, now U.S. Pat. No. 9,876,172, which is a divisional of U.S. patent application Ser. No. 14/080,340, filed Nov. 14, 2013, now U.S. Pat. No. 8,911,645, which is a divisional of U.S. patent application Ser. No. 13/178,855, filed Jul. 8, 2011, now U.S. Pat. No. 8,617,426, which is a divisional of U.S. ...

Подробнее
11-09-2014 дата публикации

NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS

Номер: US20140256805A1
Автор: Covey Douglas
Принадлежит:

The present disclosure is generally directed to neuroactive substituted cyclopenta[b]phenanthrenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

Подробнее
22-06-2017 дата публикации

ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS

Номер: US20170172195A1
Принадлежит:

A nutrient composition comprises an essential nutrient in which at least one exchangeable H atom is H and/or at least one C atom is C. The nutrient is thus protected from, inter alia, active oxygen species. 1. A nutrient composition comprising an essential nutrient in which at least one exchangeable H atom is H and/or at least one C atom is C.2. A composition according to claim 1 , wherein the essential nutrient is or comprises a naturally occurring nucleic acid claim 1 , fatty acid or amino acid.3. A composition according to claim 2 , wherein one or each. H atom bound to a C atom at a position most susceptible to oxidation is H. This application is a divisional application of the U.S. patent application Ser. No. 15/078,853, filed Mar. 23, 2016 which is a divisional application of the U.S. patent application Ser. No. 14/551,450, filed Nov. 24, 2014 and issued as U.S. Pat. No. 9,320,289, which is a divisional application of the U.S. patent application Ser. No. 12/281,957, filed Aug. 17, 2009 and issued as U.S. Pat. No. 8,906,405, which claims priority to the U.S. National Phase under 35 U.S.C. §371 of International Application No. PCT/GB2007/050112, filed Mar. 8, 2007, which claims priority to United Kingdom Application No. 0604647.8, Filed Mar. 8, 2006. The disclosures of the above-referenced applications are hereby expressly incorporated by reference in their entireties.The present Invention related to isotopically modified compounds and their use as food supplements.A currently accepted theory of ageing blames the irreversible changes in cell machinery and reduced efficiency of metabolic processes on the detrimental effects of free radicals and other reactive oxygen species (ROS) or reactive nitrogen species (RNS) which are normally present in the cell as part of the respiratory process. ROS and RNS oxidize/nitrate DNA, proteins, lipids and other cell components. Of these, protein oxidation, which converts arginine, lysine, threonine, thryptophan and proline into ...

Подробнее
04-06-2020 дата публикации

TRIAZOLES AS KV3 INHIBITORS

Номер: US20200172496A1
Принадлежит:

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders. 9. A derivative of a compound of formula (I) according to any one of to functionalised via the secondary nitrogen of the triazolone with a group L , wherein L is selected from:{'sup': −', '+', '+, 'a) —PO(OH)O.M, wherein M is a pharmaceutically acceptable monovalent counterion,'}{'sup': −', '+, 'sub': '2', 'b) —PO(O).2M,'}{'sup': −', '2+', '2+, 'sub': '2', 'c) —PO(O).D, wherein D is a pharmaceutically acceptable divalent counterion,'}{'sup': X', '−', '+', 'X, 'sub': '1-3', 'd) —CH(R)—PO(OH)O.M, wherein Ris hydrogen or Calkyl,'}{'sup': X', '−', '+, 'sub': '2', 'e) —CH(R)—PO(O).2M,'}{'sup': X', '−', '2+, 'sub': '2', 'f) —CH(R)—PO(O).D,'}{'sub': '3', 'sup': −', '+, 'g) —SO.M,'}{'sup': X', '−', '+, 'sub': '3', 'h) —CH(R)—SO.M, and'}{'sub': 2', '2', '2, 'sup': '+', 'i) —CO—CHCH—CO.M.'} This application is a continuation of U.S. patent application Ser. No. 16/181,864, filed Nov. 5, 2018 (allowed), which is a continuation of U.S. patent application Ser. No. 15/208,329, filed Jul. 12, 2016 (now U.S. Pat. No. 10,160,730) which is a continuation of U.S. patent application Ser. No. 14/403,048, filed Nov. 21, 2014 (now U.S. Pat. No. 9,422,252), which is a U.S. National Phase of International Application No. PCT/GB2013/051347, filed May 22, 2013, which designated the U.S. and claims priority to GB Application No. 1209013.0, filed May 22, 2012; GB Application No. 1209019.7, filed May 22, 2012; GB Application No. 1209020.5, filed May 22, 2012; and GB Application No. 1222393.9, filed Dec. 12, 2012; and clams the benefit of U.S. Provisional Application No. 61/702,337, filed Sep. 18, 2012, the entire contents of each of which are hereby incorporated by reference for all purposes.This invention relates to novel compounds, pharmaceutical compositions containing them and their use in therapy, in particular in the prophylaxis or ...

Подробнее
06-07-2017 дата публикации

PHOTOACID GENERATOR

Номер: US20170192352A1
Принадлежит:

A photoacid generator compound having Formula (I): 3. The photoacid generator compound of claim 2 , wherein in Formula (III):EWG is CN;{'sub': '3-20', 'R is a polycyclic Ccycloalkyl group;'}{'sup': 30', '31', '30', '31, 'sub': 2', '2', '1-6, 'Y is a single bond, —C(R)—, —N(R)—, —O—, —S—, —S(═O)—, —C(═O)—, or a combination thereof, wherein each Rand Ris independently hydrogen or a Calkyl group; and'}{'sup': '+', 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'M is the same as in .'}4. The photoacid generator compound of claim 2 , wherein in Formula (III):{'sup': 5', '6, 'sub': '2', 'Xand Xare each C(CN);'}R is hydrogen;Y is a single bond; and{'sup': 1', '2', '+, 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'Z, Z, and M are the same as in .'}9. An acid-sensitive polymer claim 1 , which is a polymerization product of the photoacid generator compound of .10. A photoresist composition claim 1 , comprising:an acid-sensitive polymer,a solvent, and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the photoacid generator compound of .'}11. A photoresist composition claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, 'the acid-sensitive polymer of , and'}a solvent.12. A method of forming an electronic device claim 10 , comprising: (a) applying a layer of the photoresist composition of on a substrate; (b) patternwise exposing the photoresist composition layer to activating radiation; and (c) developing the exposed photoresist composition layer to provide a resist relief image. This application claims priority to provisional U.S. Application No. 62/273,521, filed on Dec. 31, 2015, the content of which is incorporated herein by reference in its entirety.This invention relates to methide-containing photoacid generator (PAG) compounds.Known photoresists can provide features having resolution and size sufficient for many existing commercial applications. However for many other applications, the need exists for new photoresists that can provide highly ...

Подробнее
06-07-2017 дата публикации

PHOTORESIST COMPOSITION, COATED SUBSTRATE INCLUDING THE PHOTORESIST COMPOSITION, AND METHOD OF FORMING ELECTRONIC DEVICE

Номер: US20170192353A1
Принадлежит:

A photoresist composition, including an acid-sensitive polymer and photoacid generator compound having Formula (I): 3. The photoresist composition of claim 2 , wherein in Formula (III):EWG is CN;{'sub': '3-20', 'R is a polycyclic Ccycloalkyl group;'}{'sup': 30', '31', '30', '31, 'sub': 2', '2', '1-6, 'Y is a single bond, —C(R)—, —N(R)—, —O—, —S—, —S(═O)—, —(C═O)—, or a combination thereof, wherein each Rand Ris independently hydrogen or a Calkyl group; and'}{'sup': '+', 'M is an organic sulfonium cation or an organic iodonium cation.'}4. The photoresist composition of claim 2 , wherein in Formula (III):{'sup': 5', '6, 'sub': '2', 'Xand Xare each C(CN);'}R is hydrogen; andY is a single bond.9. The photoresist composition of claim 1 , wherein R comprises a polymerizable group claim 1 , and wherein the photoacid generator is a polymerized unit of the acid-sensitive polymer.10. A coated substrate claim 1 , comprising: (a) a substrate having one or more layers to be patterned on a surface thereof; and (b) a layer of the photoresist composition of over the one or more layers to be patterned.11. A method of forming an electronic device claim 1 , comprising: (a) applying a layer of the photoresist composition of on a substrate; (b) patternwise exposing the photoresist composition layer to activating radiation; and (c) developing the exposed photoresist composition layer to provide a resist relief image. This application claims priority to provisional U.S. Application No. 62/273,523, filed on Dec. 31, 2015, the content of which is incorporated herein by reference in its entirety.This invention relates to a photoresist composition including a methide-containing photoacid generator (PAG) compound and a method of forming an electronic device.Known photoresists can provide features having resolution and size sufficient for many existing commercial applications. However for many other applications, the need exists for new photoresists that can provide highly resolved images of ...

Подробнее
11-06-2020 дата публикации

Process for hydrocyanation of terminal alkynes

Номер: US20200181068A1
Автор: Fei Ye, Tobias Ritter
Принадлежит: STUDIENGESELLSCHAFT KOHLE MBH

The present invention refers to a process for a Rh-catalyzed Anti-Markovnikov hydrocyanation of terminal alkynes which process discloses, for the first time, the highly stereo- and regio-selective hydrocyanation of terminal alkynes to furnish E-configured alkenyl nitriles and the catalyst used in the present process.

Подробнее
27-06-2019 дата публикации

Estrogen receptor ligands, compositions and methods related thereto

Номер: US20190192476A1
Принадлежит: UNIVERSITY OF CALIFORNIA

Provided are compounds and methods for treating neurodegenerative diseases and conditions, such as multiple sclerosis, using an estrogen receptor-β ligand (ERβ ligand).

Подробнее
02-10-2014 дата публикации

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Номер: US20140296339A1
Принадлежит: Auspex Pharmaceuticals Inc

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

Подробнее
06-08-2015 дата публикации

Meta-diarylaniline or meta-diarylpyridinamine compound, preparation method and medical uses thereof

Номер: US20150218088A1

Meta-diarylaniline or meta-diarylpyridinamine compounds, methods for preparing the same and uses thereof in manufacture of a medicament. The compounds according to the present application have strong inhibitory activity (at nM level) against wild-type and various drug-resistant HIV viral strains, exhibit good druggability, and can be easily synthesized.

Подробнее
27-07-2017 дата публикации

3-ARYL PROPIOLONITRILE COMPOUNDS FOR THIOL LABELING

Номер: US20170210700A1
Принадлежит:

The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile linkers. 7. The compound according to claim 6 , wherein the compound of interest is a biomolecule claim 6 , wherein the biomolecule is an antibody or a protein. This application is a divisional of U.S. application Ser. No. 14/899,883, filed Dec. 18, 2015, which is the National Stage of International Application No. PCT/EP2014/064387, filed on Jul. 4, 2014, which claims the benefit of European Application No. 13305950.1, filed Jul. 4, 2013. The contents of which are hereby incorporated by reference in their entirety.The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile linkers.Over 90% of the human proteins contain cysteines, while in silico digest of the human proteome revealed that only about 15% of all human tryptic peptides detectable by mass spectroscopy (MS) contain at least one cysteine in their sequence. This observation combined with the presence of a highly reactive thiol group on its side chain makes cysteine an attractive target for chemical labeling. Cysteine is the only coded amino acid that carries a nucleophilic sulfhydryl (or thiol) group (—SH), which largely exceeds the reactivity of any other nucleophilic function susceptible to be present in proteins. As a result, chemospecific cysteine derivatization is by far the most widely used method for chemical tagging of proteins. Among the vast number of chemical cysteine modification methods reported in literature so far, reagents such as N-substituted maleimides, 4-vinylpyridines and iodoacetamides are most commonly used. All of them possess drawbacks preventing them from being ideal methodology for ...

Подробнее
05-08-2021 дата публикации

FTO Inhibitors

Номер: US20210238127A1
Автор: Huang Niu, Peng Shiming

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition. 2. The pharmaceutical composition of claim 1 , wherein the heterocyclic C3-C18 hydrocarbyl comprises:a 3 membered ring that is an optionally substituted: aziridine, oxirane, oxaziridine;a 4 membered ring that is an optionally substituted: azetidine, oxetane, oxazetidine;a 5 membered ring that is an optionally substituted: pyrrole, 1, 2-diazole (pyrazole), 1, 3 diazole (imidazole), thiazole, isothiazole, oxazole, isoxazole, furan, dioxole, thiophene;a 6 membered ring that is an optionally substituted: pyridine, diazine, triazine, oxazine, thiazine, dioxine, oxathiine, dithiine;a 9 membered ring that is an optionally substituted: indole, benzothiazole, benzooxazole, benzofuran, benzodioxole, benzothiophene, benzodithiole; ora 10 membered ring that is an optionally substituted: quinoline, quinoxaline, quinazoline, chromene, benzodioxine, thiochromene, benzodithiine.4. The pharmaceutical composition of claim 1 , copackaged or coformulated with a second claim 1 , different medicament for inhibiting weight gain claim 1 , promoting weight loss claim 1 , reducing serum LDL claim 1 , cholesterol claim 1 , LDL-c claim 1 , or triglycerides claim 1 , or treating obesity or an obesity related disease or Alzheimer's disease.5. A method comprising administering to a person in need thereof a composition of to inhibit weight gain claim 1 , promote weight loss claim 1 , reduce serum LDL claim 1 , cholesterol claim 1 , LDL-c claim 1 , or triglycerides claim 1 , or treat obesity or an obesity related disease or Alzheimer's disease.6. The method of ...

Подробнее
27-07-2017 дата публикации

CHARGE-TRANSPORTING MATERIAL

Номер: US20170213981A1
Автор: NAKAIE Naoki
Принадлежит: NISSAN CHEMICAL INDUSTRIES, LTD.

This charge-transporting material, which includes a charge-transporting substance, halo-tetracyanoquinodimethane, and a complexing agent comprising an amide compound such as 1,3-dimethyl-2-imidazolidinone, for example, and capable of forming a complex with halo-tetracyanoquinodimethane, and in which the halo-tetracyanoquinodimethane and complexing agent form a complex, makes it possible to provide a thin film having excellent charge-transporting properties and to realize an organic EL element having low drive voltage when said thin film is applied to a hole injection layer. 1. A charge-transporting material comprising a charge transporting substance , a halotetracyanoquinodimethane , and a complexing agent having the ability to form a complex with the halotetracyanoquinodimethane , wherein the halotetracyanoquinodimethane and the complexing agent form a complex.2. The charge-transporting material of claim 1 , wherein the complexing agent is an amide compound.3. The charge-transporting material of claim 2 , wherein the amide compound is 1 claim 2 ,3-dimethyl-2-imidazolidinone.4. The charge-transporting material of any one of to claim 2 , wherein the halotetracyanoquinodimethane is 2 claim 2 ,3 claim 2 ,5 claim 2 ,6 tetrafluoro-7 claim 2 ,7 claim 2 ,8 claim 2 ,8-tetracyanoquinodimethane.5. The charge-transporting material of which further comprises a heteropolyacid.6. The charge-transporting material of claim 1 , wherein the charge-transporting substance is a charge transporting oligomer.7. A charge-transporting thin film produced using the charge-transporting material of .8. An organic electroluminescent device comprising the charge-transporting thin film of .9. A method for producing a charge-transporting thin film claim 1 , which method comprises the steps of applying the charge transporting material of onto a substrate claim 1 , and drying the applied material.10. A method for enhancing the charge transportability of a charge-transporting thin film formed from a ...

Подробнее
23-10-2014 дата публикации

PERFUMING INGREDIENTS OF THE FLORAL AND/OR ANIS TYPE

Номер: US20140314699A1
Автор: MORETTI Robert
Принадлежит: FIRMENICH SA

The present invention concerns a compound of formula 2. A compound according to claim 1 , wherein the compound (II) is one wherein R claim 1 , Ror Rrepresents a hydrogen atom or methyl group claim 1 , R represents a hydrogen atom and X represents a CHO.3. A compound according to claim 1 , wherein the compound (I) is (4E)-4-methyl-5-(4-methylphenyl)-4-pentenal claim 1 , (4E)-2 claim 1 ,4-dimethyl-5-(4-methylphenyl)-4-pentenal claim 1 , 2 claim 1 ,4-dimethyl-5-phenyl-4-pentenal claim 1 , 4-methyl-5-phenyl-4-hexenal claim 1 , 4-methyl-5-phenyl-4-pentenal or methyl (4E)-4-methyl-5-(4-methylphenyl)-4-pentenoate.4. The compound according to claim 1 , wherein R claim 1 , Ror Rrepresents a hydrogen atom or methyl group claim 1 , Rrepresents a methyl group and X represents a CHO group.5. The compound according to claim 1 , wherein:R is an ortho, meta or para substituent of the phenyl ring and represents a hydrogen atom or a methyl or ethyl group;{'sup': '1', 'Rrepresents a methyl or ethyl group;'}{'sup': '2', 'Rrepresents a hydrogen atom or a methyl or ethyl group;'}{'sup': '3', 'Rrepresents a hydrogen atom or a methyl or ethyl group; and'}{'sup': 4', '4, 'X represents a CHO, COORor CN group, Rbeing a methyl or ethyl group.'}6. The compound according to associated with or incorporated in a solid or liquid detergent claim 1 , a fabric softener claim 1 , a perfume claim 1 , a cologne or after-shave lotion claim 1 , a perfumed soap claim 1 , a shower or bath salt claim 1 , mousse claim 1 , oil or gel claim 1 , a hygiene product claim 1 , a hair care product claim 1 , a shampoo claim 1 , a body-care product claim 1 , a deodorant or antiperspirant claim 1 , an air freshener claim 1 , a cosmetic preparation claim 1 , a fabric refresher claim 1 , an ironing water claim 1 , a paper claim 1 , a wipe or a bleach. This application is a division of U.S. application Ser. No. 13/123,642 filed Apr. 11, 2011, which is the 371 filing of International Patent Application no. PCT/IB209/054864 ...

Подробнее
09-08-2018 дата публикации

SOLID STATE MATERIALS WITH TUNABLE DIELECTRIC RESPONSE AND ROTATIONAL ANISOTROPY

Номер: US20180222826A1
Принадлежит:

A reconfigurable polar molecule includes a symmetric nonpolar molecule portion having an elongated shape defined by a longitudinal axis and lateral axis, the longitudinal axis being longer than the lateral axis; a positive ionically charged group at a first end and a negative ionically charged group at a second end of the longitudinal axis, the positive and negative ionically charged groups forming a permanent dipole; a first bridging group and a second bridging group on opposing ends of the lateral axis, the first and second bridging groups being linear nonpolar groups; and a first support portion bonded to the first bridging group, and a second support portion bonded to the second bridging group, the first bridging group and the second bridging group being nonpolar and having structures that enable free rotation of the symmetric nonpolar molecule portion through the first bridging group and the second bridging group. 1. A reconfigurable polar molecule , comprising:a symmetric nonpolar molecule portion having an elongated shape and defined by a longitudinal axis and a lateral axis, the longitudinal axis being longer than the lateral axis;a positive ionically charged group arranged on the longitudinal axis of the symmetric nonpolar molecule at a first end and a negative ionically charged group arranged on the longitudinal axis of the symmetric nonpolar molecule at a second end, the positive ionically charged group and the negative ionically charged group forming a permanent dipole through the longitudinal axis of the symmetric nonpolar molecule;a first bridging group and a second bridging group arranged on the lateral axis of the symmetric nonpolar molecule on opposing sides, the first bridging group and the second bridging group being linear nonpolar groups; anda first support portion bonded to the first bridging group, and a second support portion bonded to the second bridging group, the first bridging group and the second bridging group being nonpolar and having ...

Подробнее
25-08-2016 дата публикации

SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS

Номер: US20160244392A1
Принадлежит:

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. 145-. (canceled)47. The compound of claim 46 , wherein R claim 46 , R claim 46 , and Rare independently selected from the group consisting of —H claim 46 , —C-Calkyl claim 46 , —C-Chaloalkyl claim 46 , —C-Calkenyl claim 46 , —C-Chaloalkenyl claim 46 , —C-Calkynyl claim 46 , and —C-Chaloalkynyl claim 46 , and where at least one of R claim 46 , R claim 46 , and Ris independently selected from the group consisting of —C-Calkyl claim 46 , —C-Chaloalkyl claim 46 , —C-Calkenyl claim 46 , —C-Chaloalkenyl claim 46 , —C-Calkynyl claim 46 , and —C-Chaloalkynyl.48. The compound of claim 47 , wherein at least one of R claim 47 , R claim 47 , and Ris independently selected from the group consisting of —C-Calkyl claim 47 , —C-Chaloalkyl claim 47 , —C-Calkenyl claim 47 , —C-Chaloalkenyl claim 47 , —C-Calkynyl claim 47 , and —C-Chaloalkynyl.49. The compound of claim 46 , wherein at least two of R claim 46 , R claim 46 , and Rare independently selected from the group consisting of —C-Calkyl claim 46 , —C-Chaloalkyl claim 46 , —C-Calkenyl claim 46 , —C-Chaloalkenyl claim 46 , —C-Calkynyl claim 46 , and —C-Chaloalkynyl.50. The compound of claim 49 , wherein R claim 49 , R claim 49 , and Rare independently selected from the group consisting of —C-Calkyl claim 49 , —C-Chaloalkyl claim 49 , —C-Calkenyl claim 49 , —C-Chaloalkenyl claim 49 , —C-Calkynyl ...

Подробнее
23-08-2018 дата публикации

Novel polygodial analogs for the treatment of cancer and other proliferative diseases

Номер: US20180237362A1

The present disclosure relates generally to derivatives of polygodial and methods of use thereof. In some aspects, the present disclosure relates to using polygodial derivatives to treat cancer or other hyperproliferative diseases.

Подробнее
23-07-2020 дата публикации

Prostaglandin E Synthase Inhibitors and Methods for Utilizing the Same

Номер: US20200231583A1

Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.

Подробнее
09-09-2021 дата публикации

PROCESSES FOR PREPARING 5-FLUORO-2-METHYL-1-(4-METHYLTHIOBENZYLIDENE)-3-INDANACETONITRILE AND FOR PREPARING SULINDAC

Номер: US20210276947A1
Принадлежит:

The disclosure provides processes for preparing -fluoro--methyl--(-methylthiobenzylidene)--indanacetonitrile and for preparing sulindac, relating to the field of medicine. The former comprises mixing -fluoro--methyl--indanone, cyanoacetic acid, a first organic solvent and an acetic acid-based catalyst to proceed with a first condensation reaction to give a first condensation reaction solution, which contains -fluoro--methyl--indanacetonitrile; and mixing the first condensation reaction solution, per se, with a base, a second organic solvent and -(methylthio)benzaldehyde to proceed with a second condensation reaction to give -fluoro--methyl--(-methylthiobenzylidene)--indanacetonitrile. The process is a one-pot process without separation of -fluoro--methyl--indanacetonitrile from the solvent, shortening the synthetic route, simplifying the preparation process and improving the -fluoro--methyl--(-methylthiobenzylidene)--indanacetonitrile yield. 1. A process for preparing 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile , comprising:mixing 6-fluoro-2-methyl-1-indanone, cyanoacetic acid, a first organic solvent and an acetic acid-based catalyst to proceed with a first condensation reaction to give a first condensation reaction solution, which contains 5-fluoro-2-methyl-3-indanacetonitrile; andmixing the first condensation reaction solution, per se, with a base, a second organic solvent and 4-(methylthio)benzaldehyde to proceed with a second condensation reaction to give 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile.2. The process according to claim 1 , wherein the first condensation reaction is carried out at 100 to 140° C. for 5 to 30 hours.3. The process according to claim 1 , wherein the second condensation reaction is carried out at 50 to 90° C. for 3 to 8 hours.4. The process according to claim 1 , wherein the base comprises one or more of: sodium hydroxide claim 1 , sodium ethoxide claim 1 , sodium methylate claim 1 , potassium ...

Подробнее
31-08-2017 дата публикации

SHIP1 MODULATORS AND METHODS RELATED THERETO

Номер: US20170247389A2
Принадлежит:

Compounds of formula (II): 3. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each independently hydrogen, alkyl, alkenyl or alkynyl;'}{'sup': 4a', '4b', '7, 'or Ris hydrogen, alkyl, alkenyl or alkynyl and Ris a direct bond to the carbon to which Ris attached;'}{'sup': 5', '5, 'Ris alkyl or Ris a direct bond to the carbon at C14;'}{'sup': 6', '8', '9', '8', '9, 'sub': '2', 'Ris hydrogen, —R—ORor —R—N(R);'}{'sup': 7', '8', '9', '8', '9', '7', '4b', '7, 'sub': '2', 'Ris hydrogen, —R—OR, —R—N(R), or a direct bond to C15, provided that when Ris a direct bond to C15, Ris not a direct bond to the carbon to which Ris attached;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain;'}{'sup': '9', 'each Ris hydrogen, alkyl, optionally substituted aryl and optionally substituted aralkyl;'}{'sup': '9a', 'each Ris hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl; optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;'}{'sup': '11', 'Ris optionally substituted heteroaryl; and'}{'sup': '12', 'Ris optionally substituted heterocyclyl.'}4. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each alkyl;'}{'sup': '5', 'Ris a direct bond to the carbon at C14;'}{'sup': '6', 'Ris hydrogen;'}{'sup': '7', 'Ris hydrogen;'}{'sup ...

Подробнее
23-07-2020 дата публикации

NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME

Номер: US20200235304A1
Принадлежит:

Provided is a compound of Chemical Formula : 2. The compound according to claim 1 , wherein:{'sub': 1', '2, 'Rand Rare each independently cyano or 2,3,5,6-tetrafluoro-4-cyanophenyl.'}3. The compound according to claim 1 , wherein:{'sub': 3', '4, 'Rand Rare each independently hydrogen or deuterium.'}5. The compound according to claim 1 , wherein:{'sub': 1-60', '1-60', '1-60', '1-60', '1-60, 'Ar is phenyl, wherein said phenyl is substituted with 1 to 5 substituents each selected from the group consisting of a substituted or unsubstituted Calkyl, a substituted or unsubstituted Calkoxy, a substituted or unsubstituted Chaloalkyl, a substituted or unsubstituted Chaloalkoxy, halogen, cyano, and tri(Calkyl)silyl.'}6. The compound according to claim 1 , wherein:Ar is phenyl, wherein said phenyl is substituted with 1 to 5 substituents each selected from the group consisting of fluoro, trifluoromethyl, trifluoromethoxy, and cyano.9. An organic light emitting device claim 1 , comprising:a first electrode;a second electrode that is disposed opposite to the first electrode; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'one or more organic material layers that are disposed between the first electrode and the second electrode, wherein one or more layers of the organic material layers include the compound of .'}10. The organic light emitting device according to claim 9 , wherein:the organic material layer includes a hole injection layer, wherein the hole injection layer is formed of the compound alone or is formed by doping the compound.11. The organic light emitting device according to claim 9 , wherein:the organic material layer includes a doped hole transport layer, wherein the doped hole transport layer is formed by doping the hole transport material with the compound.12. The organic light emitting device according to claim 9 , wherein:a first stack emitting light of a first color, a second stack emitting light of a second color, and a charge generating layer that ...

Подробнее
30-07-2020 дата публикации

Methylene-cycloalkylacetate derivatives and their use in treatment of neurotropic conditions

Номер: US20200239398A1

Methylene-cycloalkylacetate compounds and derivatives thereof and their use in methods for treatment of neurotropic conditions.

Подробнее
08-08-2019 дата публикации

PHOTOACID GENERATOR

Номер: US20190243239A1
Принадлежит:

A photoacid generator compound having Formula (I): 3. The photoacid generator compound of claim 2 , wherein in Formula (III):{'sup': 5', '6, 'sub': '2', 'Xand Xare each C(CN);'}{'sub': '3-20', 'R is a polycyclic Ccycloalkyl group; and'}{'sup': 30', '31', '30', '31, 'sub': 2', '2', '1-6, 'Y is a single bond, —C(R)—, —N(R)—, —O—, —S—, —S(═O)—, —C(═O)—, or a combination thereof, wherein each Rand Ris independently hydrogen or a Calkyl group.'}4. The photoacid generator compound of claim 2 , wherein in Formula (III):{'sup': 5', '6, 'sub': '2', 'Xand Xare each C(CN);'}R is hydrogen; andY is a single bond.9. The photoacid generator compound of claim 1 , wherein R is a polymerizable group.10. The photoacid generator compound of claim 2 , wherein R is a polymerizable group.12. A photoresist composition claim 2 , comprising:an acid-sensitive polymer,a solvent, and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a photoacid generator compound of .'}13. A photoresist composition claim 2 , comprising:{'claim-ref': {'@idref': 'CLM-00011', 'claim 11'}, 'the acid-sensitive polymer of , and'}a solvent.14. A method of forming an electronic device claim 12 , comprising: (a) applying a layer of the photoresist composition of on a substrate; (b) patternwise exposing the photoresist composition layer to activating radiation; and (c) developing the exposed photoresist composition layer to provide a resist relief image.15. A method of forming an electronic device claim 13 , comprising: (a) applying a layer of the photoresist composition of on a substrate; (b) patternwise exposing the photoresist composition layer to activating radiation; and (c) developing the exposed photoresist composition layer to provide a resist relief image.17. A photoresist composition claim 13 , comprising:an acid-sensitive polymer,a solvent, and{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'a photoacid generator compound of .'}18. A photoresist composition claim 13 , comprising:{'claim-ref': {'@idref': 'CLM ...

Подробнее
07-09-2017 дата публикации

SHIP1 MODULATORS AND METHODS RELATED THERETO

Номер: US20170253596A2
Принадлежит:

Compounds of formula (I): 2. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is substituted with one hydrogen;C14 is substituted with one hydrogen;C15 is substituted with two hydrogens;{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 4a', '4b', '7', '3, 'sub': 2', '2', '2', '2', '3', '3, 'Ris hydrogen or alkyl, Ris a direct bond to the carbon to which Ris attached, and Ris —CHNHor —CHN(H)C(O)(CH)CH;'}{'sup': '5', 'Ris alkyl;'}{'sup': '6', 'Ris hydrogen;'}{'sup': '7', 'Ris hydrogen;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain; and'}{'sup': '9', 'each Ris independently hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl.'}3. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is substituted with one hydrogen;C14 is substituted with one hydrogen;C15 is substituted with two hydrogens;{'sup': '1', 'Ris —OH;'}{'sup': '2', 'sub': '2', 'Ris —CH—OH;'}{'sup': 4a', '4b', '7', '3, 'sub': 2', '2', '2', '2', '3', '3, 'Ris hydrogen or methyl, Ris a direct bond to the carbon to which Ris attached, and Ris —CHNHor —CHN(H)C(O)(CH)CH;'}{'sup': '5', 'Ris methyl;'}{'sup': '6', 'Ris hydrogen; and'}{'sup': '7', 'Ris hydrogen.'}4. The compound of selected from:(1S,3S,4R)-4-((3aS,6S,7R,7aS)-7-(aminomethyl)-3,3a-dimethyl-3a,4,5,6,7,7a-hexahydro-1H-inden-6-yl)-3-(hydroxymethyl)-4-methylcyclohexanol; andN-(((3aR,6S,7R,7aS)-6-((1R,2S,4S)-4-hydroxy-2-(hydroxymethyl)-1-methylcyclohexyl)-3a-methyl-3a,4,5,6,7,7a-hexahydro-1H-inden-7-yl)methyl)pentanamide.6. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is ...

Подробнее
30-09-2021 дата публикации

METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS

Номер: US20210300928A1
Принадлежит:

In one aspect, the disclosure relates to methods for preparation of intermediates useful for the preparation of aryl-cycloheptene scaffolds. In a further aspect, the disclosed methods pertain to the preparation of compounds comprising an aryl-cycloheptene structure. The disclosed methods utilize abundant starting materials and simple reaction sequences that can be used to modularly and scalably assemble common such cores. In various aspects, the present disclosure pertains to compounds prepared using the disclosed methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Подробнее
27-11-2014 дата публикации

Compounds and Methods for Preparing Substituted 3-(1-amino-2-methylpentane-3-yl)phenyl Compounds

Номер: US20140350283A1
Принадлежит:

Compounds and methods for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds from an isomerically pure starting material are described. In particular, methods of preparing a 3-(1-(dimethylamino)-2-methylpentane-3-yl)phenol as a substantially optically pure (R,R) stereoisomer are described. Using a method of the present invention, only the (R,R) and (S,S) stereoisomers of the target compound are produced, increasing the yield and stereoselectivity of the desired (R,R) stereoisomer. 17-. (canceled)9. (canceled)10. The method according to claim 8 , wherein the (R claim 8 ,R) stereoisomer is separated from the (S claim 8 ,S) stereoisomer by chromatography.11. The method of claim 10 , wherein the chromatography comprises one or more selected from the group consisting of batch chromatography claim 10 , supercritical fluid chromatography claim 10 , and continuous chromatography.12. The method of claim 10 , wherein the chromatography comprises a simulated moving bed chromatography.16. (canceled)18. The method according to claim 17 , wherein Rrepresents a hydrogen claim 17 , and Rrepresents a methyl.20. The method according to claim 19 , wherein Rrepresents a hydrogen claim 19 , and Rrepresents a methyl.22. The method according to claim 21 , wherein Rrepresents a hydrogen claim 21 , and Rrepresents a methyl.2324-. (canceled) Embodiments of the present invention relate to compounds and methods for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds with improved stereoselectivity and increased yield of the desired stereoisomers and method for preparing the compounds. In particular, the present invention relates compounds and methods for preparing a substantially optically pure (R,R) stereoisomer of 3-(1-(dimethylamino)-2-methylpentane-3-yl)phenol (tapentadol) from a substantially isomerically pure starting material.Substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds have potent analgesic effects. One 3-(1-amino-2-methylpentane-3 ...

Подробнее
13-09-2018 дата публикации

Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity

Номер: US20180256517A1
Принадлежит: Auspex Pharmaceuticals Inc

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

Подробнее
06-08-2020 дата публикации

PREPARATION OF 2-CYCLOHEXYLIDEN-2-PHENYL ACETONITRILE AND ODORIFEROUS STRUCTURAL ANALOGS THEREOF

Номер: US20200247745A1
Принадлежит: Agan Aroma & fine chemicals Ltd.

A process of preparing 2-cyclohexyliden-2-phenyl acetonitrile or odoriferous structural analogs thereof, represented by Formula I: 2. The process of claim 1 , wherein said contacting is for a time period of from 1 hour to 5 hours.3. The process of claim 2 , wherein said contacting comprises gradually contacting said mixture with said alkaline substance during a time period of 0.5-2 hours claim 2 , to thereby obtain said reaction mixture claim 2 , and heating said reaction mixture at said temperature for an additional time period of from 0.5 to 3 hours.4. The process of claim 1 , wherein a mol ratio of said compound of Formula III and said compound of Formula II ranges from 2:1 to 1:2.5. The process of claim 1 , wherein a mol ratio of said compound of Formula III and said compound of Formula II is no more than 2:1.6. The process of claim 4 , wherein said ratio is 1:1.7. The process of claim 1 , wherein said reaction mixture is devoid of an organic solvent.8. The process of claim 1 , wherein said alkaline substance is sodium hydroxide.9. The process of claim 1 , wherein said contacting is with an aqueous solution containing said alkaline substance.10. The process of claim 9 , wherein a concentration of said alkaline substance in said aqueous solution is from 1 to 90% by weight.11. The process of claim 1 , wherein a mol ratio of said alkaline substance and said compound of Formula II is from 10:1 to 1:10.12. The process of claim 1 , wherein a mol ratio of said phase transfer catalyst and said compound of Formula II is ranges from 1:2000 to 1:1.13. The process of claim 1 , wherein a mol ratio of said phase transfer catalyst and said compound of Formula II is at least 1:5.14. The process of claim 1 , wherein a mol ratio of said phase transfer catalyst and said compound of Formula III is at least 1:5.15. The process of claim 1 , further comprising claim 1 , subsequent to said contacting claim 1 , isolating the compound of Formula I from said reaction mixture claim 1 , to ...

Подробнее
13-09-2018 дата публикации

PERFUME SYSTEMS

Номер: US20180258371A1
Принадлежит:

The present application relates to perfume raw materials, perfume delivery systems and consumer products comprising such perfume raw materials and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials and compositions, including the delivery systems, disclosed herein expand the perfume communities' options as such perfume raw materials can provide variations on character and such compositions can provide desired odor profiles. 2. A perfume according to comprising claim 1 , based on total perfume weight claim 1 , from about 0.0001% to about 50% of said perfume raw material.3. A consumer product comprising the perfume according to and an adjunct ingredient.4. A consumer product comprising the perfume according to claim 2 , said consumer product being a cleaning and/or treatment composition and comprising an adjunct ingredient.5. A consumer product according to claim 4 , said consumer product being a fabric and/or hard surface cleaning and/or treatment composition claim 4 , said composition comprising claim 4 , based on total composition weight claim 4 , from about 0.00001% to about 35% of said perfume.6. A consumer product according to claim 4 , said consumer product being a detergent claim 4 , said detergent comprising claim 4 , based on total detergent weight claim 4 , from about 0.00001% to about 35% of said perfume.7. A consumer product according to claim 4 , said consumer product being a highly compacted consumer product claim 4 , said highly compacted consumer product comprising claim 4 , based on total highly compacted consumer product weight claim 4 , from about 0.00001% to about 35% of said perfume.8. A perfume delivery system comprising claim 1 , based on total delivery system weight claim 1 , from about 0.001% to about 99% of the perfume of claim 1 , said perfume delivery system being a polymer assisted delivery system; a molecule- ...

Подробнее
01-10-2015 дата публикации

2-CYCLOALKYL RESORCINOL CANNABINERGIC LIGANDS

Номер: US20150274623A1
Принадлежит: Northeastern Uiversity

The present invention relates to novel 2-cycloalkyl resorcinol compounds; to pharmaceutical compositions comprising the compounds; and to methods of preparing the compounds and uses thereof. The disclosed compounds can bind to and modulate the cannabinoid receptors and thus, they are specific ligands for these receptors. The invented compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response may be useful to treat a number of physiological conditions. 2. The compound of claim 1 , wherein each of Rand Rare independently selected from the group consisting of —H claim 1 , —SH claim 1 , —NH claim 1 , —OH claim 1 , —O-alkyl claim 1 , —OSi(alkyl) claim 1 , —OC(O)CH claim 1 , and —O-alkyl-COOR (wherein R is selected from the group consisting of H and alkyl).3. The compound of claim 2 , wherein Rand Rare —OH.4. The compound of claim 1 , wherein Ris selected from the group consisting of -cycloalkyl-R claim 1 , -heterocyclyl-Rand -adamantyl.5. The compound of claim 4 , wherein Ris selected from the group consisting of -cycloalkyl-Rand -heterocyclyl-Rand Ris selected from the group consisting of —(CH)-A-(CH)—Rand —(CH)-A-(CH)—B—R.6. The compound of claim 5 , wherein Ris —(CH)-A-(CH)—R.7. The compound of claim 5 , wherein Ris —(CH)-A-(CH)—B—R.8. The compound of claim 6 , wherein A is selected from the group consisting of —CH—CH— claim 6 , —CH═CH— claim 6 , —C≡C— claim 6 , —O— claim 6 , —S— claim 6 , —NH— claim 6 , —C(O)— claim 6 , —C(O)O— claim 6 , —C(O)NH— and —NHC(O)—.9. The compound of claim 8 , wherein A is selected from the group consisting of —CH—CH— and —CH═CH—.10. The compound of claim 7 , wherein each of A and B are independently selected from the group consisting of —CH—CH— claim 7 , —CH═CH— claim 7 , —C≡C— claim 7 , —O— claim 7 , —S— claim 7 , —NH— claim 7 , —C(O)— claim 7 , —C(O)O— claim 7 ...

Подробнее
08-10-2015 дата публикации

MALONONITRILE COMPOUNDS FOR CONTROLLING ANIMAL PESTS

Номер: US20150282481A1
Принадлежит:

The invention relates to the use of a compound of formula (I) 133-. (canceled)35. The method according to claim 34 , wherein{'sup': 5', '6', 'a, 'sub': 5', '1', '6', '2', '6', '2', '6, 'each R, Ris independently halogen, cyano, azido, nitro, —SCN, SF, C-Calkyl, C-Calkenyl, C-Calkynyl, wherein the carbon atoms of the aforementioned aliphatic radicals are unsubstituted or substituted with one or more R;'}{'sub': 3', '8', '3', '8, 'sup': 'b', 'C-Ccycloalkyl or C-Ccycloalkenyl, wherein the carbon atoms of the aforementioned cycloaliphatic radicals are unsubstituted or substituted with one or more R;'}{'sup': 'c', 'phenyl unsubstituted or substituted with up to 5 R;'}{'sub': '2', 'sup': 'd', 'a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or aromatic heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from N, O, S, NO, SO, SO, wherein the aforementioned ring is unsubstituted or substituted with up to 5 R;'}{'sup': e', 'f', 'f', 'h', 'h', 'i', 'i', 'm', 'm', 'm', 'f', 'i', 'm', 'm, 'sub': 3', 'x', 'x', '2, 'Si(R), OR, SR, OS(O)R, S(O)R, N(R), N(R)C(═O)R, OC(═O)R, C(═O)R, C(═O)OR, C(═NR)R, C(═S)R;'}or{'sup': 5', 'K', 'K', '5, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '3', '3, 'two Ron two adjacent carbon atoms present on one phenyl ring are together a bridge selected from CHCHCHCH, N═CH—CH═CH, CH═N—CH═CH, N═CH—N═CH, OCHCHCH, OCH═CHCH, CHOCHCH, OCHCHO, OCHOCH, CHCHCH, CH═CHCH, CHCHO, CH═CHO, CHOCH, CHC(═O)O, C(═O)OCH, O(CH)O, SCHCHCH, SCH═CHCH, CHSCHCH, SCHCHS, SCHSCH, CHCHS, CH═CHS, CHSCH, CHC(═S)S, C(═S)SCH, S(CH)S, CHCHNR, CHCH═N, CH═CH—NR, OCH═N, SCH═N and form together with the carbon atoms the two Rare bonded to a 5- or 6-membered partially unsaturated or aromatic carbocyclic or heterocyclic ring, wherein the ring is ...

Подробнее
08-10-2015 дата публикации

COMPOSITION COMPRISING A DIBENZOYLMETHANE SCREENING AGENT AND A MEROCYANINE DICYANO OR CYANOACETATE DERIVATIVE; METHOD FOR THE PHOTOSTABILIZATION OF THE DIBENZOYLMETHANE SCREENING AGENT

Номер: US20150284330A1
Принадлежит:

The present invention relates to a cosmetic composition comprising the combination i) of at least one screening agent of the dibenzoylmethane derivative type and ii) of at least one specific merocyanine dicyano or cyanoacetate derivative. It also relates to a method for the photostabilization, with regard to radiation, of at least one screening agent of the dibenzoylmethane derivative type by an effective amount of at least one specific merocyanine dicyano or cyanoacetate derivative. This application is a Divisional of U.S. application Ser. No. 13/634,176 filed on Nov. 27, 2012, which is the National Phase filing under 35 U.S.C. §371 of PCT/EP2011/053378 filed on Mar. 7, 2011; and this application claims priority to Application No. 1051819 filed in France on Mar. 15, 2010 under 35 U.S.C. §119, and this application claims priority to Application No. 1058686 filed in France on Oct. 22, 2010 under 35 U.S.C. §119; and this application claims the benefit of U.S. Provisional Application No. 61/282,735 filed on Mar. 24, 2010. The entire contents of each application is hereby incorporated by reference.The present invention relates to a cosmetic composition comprising the combination i) of at least one screening agent of the dibenzoylmethane derivative type and ii) of at least one specific merocyanine dicyano or cyanoacetate derivative, the definition of which will be given below.It also relates to a method for the photostabilization, with regard to radiation, of at least one screening agent of the dibenzoylmethane derivative type by an effective amount of at least one specific merocyanine dicyano or cyanoacetate derivative, the definition of which will be given below.It is known that light radiation with wavelengths of between 280 nm and 400 nm makes possible browning of the human epidermis and that rays with wavelengths more particularly of between 280 and 320 nm, known under the name of UV-B, cause erythemas and skin burns which may be harmful to the development of ...

Подробнее
29-08-2019 дата публикации

PROCESS FOR THE PREPARATION OF PHENYLMALONIC ACID DINITRILES

Номер: US20190263752A1
Принадлежит: SYNGENTA PARTICIPATIONS AG

Process for the preparation of a compound of Formula (I), the process comprising the reaction of a compound of Formula (II) with malononitrile in the presence of a base and a palladium catalyst, Formula (II) wherein X, Y and Z, independently of each other, represent fluoro, chloro or Calkyl; and L is a leaving group; with the proviso that 1 or 2 of X and Y are, independently of each other, fluoro or chloro. 2. The process according to claim 1 , comprising steps (i) and (ii) claim 1 , wherein:{'sup': '−', '(i) malononitrile is reacted with base to form a malononitrile anion ([NCCHCN]); and'}(ii) the compound of Formula (II) is reacted with the malononitrile anion of step (i) in the presence of palladium catalyst to form a compound of Formula (I).3. The process according to claim 1 , wherein X is methyl claim 1 , Y is chloro and Z is methyl.4. The process according to claim 1 , wherein L is bromo.5. The process according to claim 1 , wherein the base is an alkali metal hydroxide claim 1 , preferably sodium hydroxide.6. The process according to claim 1 , wherein the palladium catalyst is prepared in situ from palladium (1I) or palladium (0) compounds by complexing with phosphine ligands.7. The process according to claim 1 , wherein the process is carried out in the presence of a dipolar aprotic solvent claim 1 , preferably N-methyl-2-pyrrolidone.8. The process according to claim 1 , wherein the process is carried out at 110 to 150° C.11. The compound according to claim 10 , which is 2-(4-chloro-2 claim 10 ,6-dimethyl-phenyl)propanedinitrile.13. The process according to claim 9 , wherein the acid is sulphuric acid.14. The process according to claim 12 , wherein the process is further carried out in the presence of toluene or xylene.15. The process according to claim 1 , wherein the process is carried out at 120 to 155° C. The present invention relates to a process for the preparation of certain phenyl acetic acid derivatives, to intermediate dinitrile compounds useful ...

Подробнее
05-09-2019 дата публикации

METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS

Номер: US20190270700A1
Принадлежит:

In one aspect, the disclosure relates to methods for preparation of terpene and terpene-like molecules. In a further aspect, the disclosure relates to the products of the disclosed methods, i.e., terpene and terpene-like molecules prepared using the disclosed methods. Intermediates for the synthesis of a wide variety of terpenoids are γ-allyl Knoevenagel adducts or quasi γ-allyl Knoevenagel adducts are disclosed. In various aspects, methods of preparing terpenoids through these intermediates are disclosed. The methods can comprise a-alkylation of an allylic electrophile followed by ring-closure metathesis to a polycyclic terpenoid structure. In a further aspect, the disclosure pertains to terpenoid frameworks, and compounds prepared via disclosed oxidation and substitution reactions on the disclosed terpenoid frameworks. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. 13. The method of claim 8 , wherein X is acetoxy claim 8 , t-butyloxycarbonoxy claim 8 , or Br.15. The method of claim 1 , further comprising:reacting the γ-allyl Knoevenagel adduct or a quasi γ-allyl Knoevenagel adduct with an allyl comprising electrophile to form an α,γ-diallyl Knoevenagel adduct or quasi α,γ-diallyl Knoevenagel adduct; andcatalyzing a ring-closure metathesis of the α,γ-diallyl Knoevenagel adduct or quasi α,γ-diallyl Knoevenagel adduct thereby forming a compound with a terpenoid framework. This Application claims the benefit of U.S. Provisional Application No. 62/394,852, filed on Sep. 15, 2016, which is incorporated herein by reference in its entirety.Structurally complex terpenoid natural products have been recognized as important therapeutic agents. Many terpenoid natural products contain a polycyclic core bearing a medium-sized 7- to 9-membered ring; examples of which are illustrated in . For example, taxol and ingenol are clinically used for the treatment of cancer and ...

Подробнее
05-10-2017 дата публикации

ELECTRODE ACTIVE MATERIAL COMPRISING QUINODIMETHANE DERIVATIVES, AND DERIVATIVES, AND SECONDARY BATTERY COMRISING THE SAME

Номер: US20170288228A1
Принадлежит:

An electrode active material including at least one selected from a quinodimethane derivative and a lithium salt thereof, wherein the quinodimethane derivative has at least three linearly-condensed aryl groups and at least two quinodimethane moieties. 1. An electrode active material comprising:at least one selected from a quinodimethane compound and a lithium salt thereof, wherein the quinodimethane compound comprises at least three linearly-condensed aryl groups and at least two quinodimethane moieties.3. The electrode active material of claim 2 , wherein at least one selected from Rto Ris a cyano group.4. The electrode active material of claim 2 , wherein Arto Arare each independently selected froma benzene group, a naphthalene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, and a pentaphene group; and{'sub': 1', '20', '1', '20', '31', '32', '33', '31', '32', '31', '32', '31', '2', '31', '31', '32, 'a benzene group, a naphthalene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, naphthacene group, a picene group, a perylene group, and a pentaphene group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C-Calkyl group, a C-Calkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, —Si(Q)(Q)(Q), —N(Q)(Q), —B(Q)(Q), —C(═O)(Q), —S(═O)(Q), and —P(═O)(Q)(Q),'}{'sub': 31', '33', '1', '10', '1', '10, 'wherein Qto Qare each independently selected from a C-Calkyl group, a C-Calkoxy group, a phenyl group, a biphenyl group, a terphenyl group, and a naphthyl group.'}7. The electrode active material of claim 6 , wherein n is an integer selected from 1 to 4.8. The electrode ...

Подробнее
11-10-2018 дата публикации

LSD1 INHIBITORS AND USES THEREOF

Номер: US20180290976A1
Принадлежит:

Provided are novel compounds of Formula (I): 2. The compound of claim 1 , wherein Ris hydrogen.3. The compound of claim 1 , wherein{'sup': 1', 'X, 'Ris selected from carbocyclyl, heterocyclyl, aryl and heteroaryl, each of which being optionally substituted with up to 3 substituents independently selected from R;'}{'sup': 2', '3, 'sub': 1', '4, 'each of Rand Ris independently selected from hydrogen, halo, and C-Calkyl;'}{'sup': '5', 'sub': 1', '4, 'each Ris independently selected from hydrogen and C-Calkyl;'}{'sup': '6', 'Ris hydrogen;'}{'sup': 8', 'Y, 'sub': 0', '4', '0', '4', '0', '4', '0', '4, 'Ris selected from —(C-Calkylene)-carbocyclyl, —(C-Calkylene)-heterocyclyl, —(C-Calkylene)-aryl, and —(C-Calkylene)-heteroaryl, wherein said carbocyclyl, heterocyclyl, aryl, and heteroaryl are each optionally substituted with up to 3 substituents independently selected from R;'}{'sup': X', 'Y', 'c', 'a', 'b', 'c', 'd', 'c', 'e', 'f', 'c', 'c', 'c', 'c', 'c', 'c', 'e', 'f', 'd', 'c', 'e', 'f', 'd', 'c', 'd', 'c', 'e', 'f', 'd', 'c', 'e', 'f', 'd', 'e', 'f', 'd', 'e', 'f', 'c', 'c', 'c', 'd', 'c', 'g', 'h', 'c', 'c', 'e', 'f', 'c', 'X', 'Y, 'sub': i', '2', '2', '1', '6', '2', '1-4', '2', '1-4', '2', '1-4', '2', '1-4', '1', '6', '2', '1-4', '2', '1-4', '2', '1-4', '2', '1-4', '2', 'i', '1', '3', '1', '3', '1', '3', '1', '3', '1', '3', '1', '3, 'Rand Rare each independently selected from halogen, —CN, —OR, —NRR, —S(O)R, —NRS(O)R, —S(O)NRR, —C(═O)OR, —OC(═O)OR,—OC(═O)R, —OC(═S)OR, —C(═S)OR, —O(C═S)R, —C(═O)NRR, —NRC(═O)OR, —C(═S)NRR, —NRC(═S)R, —NR(C═O)OR, —O(C═O)NRR, —NR(C═S)OR, —O(C═S)NRR, —NR(C═O)NRR, —NR(C═S)NRR, —C(═S)R, —C(═O)OR, (C-C)alkyl, cycloalkyl, —(CH)-cycloalkyl, heterocyclyl, —(CH)-heterocyclyl, aryl, —(CH)-aryl, heteroaryl and —(CH)-heteroaryl, wherein each of the (C-C)alkyl, cycloalkyl, —(CH)-cycloalkyl, heterocyclyl, —(CH)-heterocyclyl, aryl, —(CH)-aryl, heteroaryl and —(CH)-heteroaryl are optionally substituted with halogen, OR, —NO, —CN, —NRC(═O)OR, —NRR, —S(O ...

Подробнее
10-09-2020 дата публикации

Process and intermediate

Номер: US20200283374A1
Принадлежит: SYNGENTA PARTICIPATIONS AG

Process for the preparation of a compound of Formula (I): the process comprising the reaction of a compound of Formula (II) with malononitrile in the presence of a base and a palladium catalyst, wherein X, Y and Z, independently of each other, represent fluoro, chloro or C 1-4 alkyl; and L is a leaving group; with the proviso that 1 or 2 of X and Y are, independently of each other, fluoro or chloro.

Подробнее
10-09-2020 дата публикации

NITRILE OXIDE COMPOUND, COMPOSITION, MODIFIED POLYOLEFIN AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING BLOCK COPOLYMER

Номер: US20200283429A1
Принадлежит: MITSUBISHI CHEMICAL CORPORATION

A nitrile oxide compound which is a compound represented by General Formula [I], in which a melting point is 25° C. to 300° C., and an equivalent of nitrile oxide is 1.0 to 4.5 mmol/g. 2. The nitrile oxide compound according to claim 1 ,{'sup': 1', '2, 'wherein, in General Formula [I], Rand Rare each independently an aryl group having 6 to 8 carbon atoms.'}3. The nitrile oxide compound according to claim 2 ,wherein, in General Formula [I],s is 2, andA is an alkylene group having 2 to 10 carbon atoms.4. The nitrile oxide compound according to claim 3 ,wherein, in General Formula [I],A is a 1,2-ethylene group, a 1,3-propylene group, a 2-methyl-1,3-propylene group, a 2,2-dimethyl-1,3-propylene group, a 1,4-butylene group, a 1,5-pentylene group, a 1,6-hexylene group, a 1,7-heptylene group, a 1,8-octylene group, a 3-methyl-1,5-pentylene group, a 1,4-cyclohexylene group, a 1,4-cyclohexadimethylene group, a 1-methyl-1,2-ethylene group, or a 1-methyl-1,3-propylene group.6. The nitrile oxide compound according to claim 5 ,wherein, in General Formula [II],m is 1, and{'sup': '5', 'Ris a group represented by General Formula [IV], and'}in General Formula [IV],n is 1, and{'sup': 18', '19, 'Q is —C(R)(R)—.'}8. The nitrile oxide compound according to claim 7 ,wherein, in General Formula [V],{'sup': b', '20', '20, 'Ris a hydroxy group, a mercapto group, a carboxy group, an amino group, an amino group having a substituent, an amide group, —OR(where Ris an alkyl group or an aryl group), or a heterocyclic ring.'}9. A composition comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'the nitrile oxide compound according to ; and'}a substance that can react with a nitrile oxide group of the nitrile oxide compound.10. The composition according to claim 9 ,wherein the substance that can react with a nitrile oxide group is a resin or a rubber.11. A method for producing a modified polyolefin claim 9 , the method comprising:performing an addition reaction of a polyolefin having a ...

Подробнее
25-10-2018 дата публикации

SINGLE PHASE LIQUIDS OF ALKANOLAMINE SALTS OF DICAMBA

Номер: US20180303091A1
Принадлежит: Taminco BVBA

The invention is a herbicidal composition containing an alkanolamine salt of an dicamba capable of remaining as a single phase liquid over a period of at least 1 week and containing low amounts of water and high loadings of the salt. Such herbicidal compositions are capable of remaining liquid in the absence of high amounts of water, thereby enhancing their capacity to remain liquid over an extended period of time when exposed to environmental conditions to improve their effectiveness to transport the active salt through a leafy substrate and can reduce transportation costs by increasing the salt loading without compromising the stability of the composition. 1. A herbicidal composition comprising water and an alkanolamine salt , said alkanolamine salt comprising the reaction product of an alkanolamine compound with dicamba , wherein said alkanolamine salt is capable of remaining a single phase liquid for at least 1 week , said capability determined by subjecting said alkanolamine salt to the following test conditions: 2 ml of a sample containing said alkanolamine salt and less than 5 wt. % water , based on the weight of the sample , and no non-aqueous solvents is placed onto a glass surface and exposed to the atmosphere at a temperature within a range of 20° C. to 25° C. and at approximately 1 atmosphere.2. The herbicidal composition of claim 1 , wherein sample undergoing said test does not contain solids dispersed throughout the liquid.3. The herbicidal composition of claim 1 , wherein the sample undergoing said test contains no added solvent other than water.4. The composition of claim 3 , wherein the sample undergoing the test conditions contains water in an amount of no more than 3 wt. % based on the weight of the sample claim 3 , and no other added solvents.5. The herbicidal composition of claim 4 , wherein the herbicidal composition contains water present in an amount of not more than 10 wt. % based on the weight of the herbicidal composition.6. The herbicidal ...

Подробнее
25-10-2018 дата публикации

ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS

Номер: US20180303145A1
Принадлежит:

A nutrient composition comprises an essential nutrient in which at least one exchangeable H atom is H and/or at least one C atom is C. The nutrient is thus protected from, inter alia, active oxygen species. 118-. (canceled)19. A medicament composition , comprising an amount of an isotopically modified compound that is effective to reduce the extent of oxidation of a bodily constituent in a patient to which the isotopically modified compound is administered.20. The medicament composition of claim 19 , wherein the isotopically modified compound is a nucleic acid claim 19 , lipid claim 19 , or amino acid.21. The medicament composition of claim 20 , wherein the isotopically modified compound is a lipid.22. The medicament composition of claim 21 , wherein the lipid is a deuterated fatty acid.23. The medicament composition of claim 22 , wherein the deuterated fatty acid is a deuterated ω-3 fatty acid or a deuterated ω-6 fatty acid.24. The medicament composition of claim 22 , wherein the deuterated fatty acid is deuterated at least at one or more bis-allylic positions.25. The medicament composition of claim 22 , wherein the deuterated fatty acid is 11-D-linoleic acid or 11 claim 22 ,11-D2-linoleic acid.26. The medicament composition of claim 21 , wherein the lipid is a deuterated fatty acid ester.27. The medicament composition of claim 26 , wherein the lipid is a 11-D-linoleic acid ester or 11 claim 26 ,11-D2-linoleic acid ester.28. The medicament composition of claim 21 , wherein the bodily constituent of the patient is a fat.29. The medicament composition of claim 20 , wherein the isotopically modified compound is a nucleic acid or an amino acid.30. The medicament composition of claim 29 , wherein the amino acid is selected from the group consisting of Phe claim 29 , Val claim 29 , Trp claim 29 , Thr claim 29 , Ile claim 29 , Met claim 29 , His claim 29 , Leu claim 29 , Lys and Arg.31. The medicament composition of claim 29 , wherein the amino acid is selected from the ...

Подробнее
03-11-2016 дата публикации

Triazoles as kv3 inhibitors

Номер: US20160318882A1

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.

Подробнее
03-11-2016 дата публикации

GAMMA-AMINOBUTYRIC ACID (GABA) ANALOGUES FOR THE TREATMENT OF PAIN AND OTHER DISORDERS

Номер: US20160318885A1
Принадлежит: Novassay S.A.

A compound of Formula (1) wherein Rrepresents hydrogen, halo, a C1-C4 alkyl group, a C1-C4 alkylhalide group, a C1-C4 alkoxy-C2-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group or a C3-C7 cyclo alkyl group; Rrepresents Formula (1)′ or Formula (1)″ a tautomer thereof; and Rrepresents hydrogen, a C1-C4 alkyl group, a C1-C4 alkoxy-C2-C4 alkyl group or a C7 cyclo alkyl group; or a pharmaceutically acceptable salt or solvate thereof. Processes to prepare said compounds and novel intermediates are also claimed. Such compound finds utility in treating neuropathic pain and disorders of the central nervous system. 4. A compound according to in which Rrepresents ethyl.8. A pharmaceutical composition comprising a compound as defined in and a pharmaceutically acceptable carrier therefor.9. A method of treating neuropathic pain in a patient in need thereof comprising administering a therapeutically effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt or solvate thereof as defined in .10. A method of treating disorders of the central nervous system in a patient in need thereof comprising administering a therapeutically effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt or solvate thereof as defined in .11. A compound of Formula 1 as defined in for use in the treatment of neuropathic pain.12. A compound of Formula 1 as defined in for use in the treatment of diseases of the central and/or the peripheral nervous system.13. A compound for the use according to for use in the treatment of diseases of the central nervous system.14. A compound of Formula 1 as defined in for use in the treatment headache and migraine.15. A compound of Formula I as defined in for use in the treatment of pain associated with a CNS disorder claim 1 , wherein the CNS disorder is selected from the group consisting of epilepsy claim 1 , ischemic cerebrovascular disease claim 1 , stroke claim 1 , cerebral neoplasms claim 1 , Alzheimer's ...

Подробнее